For the fiscal year ended December 30, 2012
|
Commission file number 1-3215
|
New Jersey
|
|
22-1024240
|
(State of incorporation)
|
|
(I.R.S. Employer Identification No.)
|
|
|
|
One Johnson & Johnson Plaza
New Brunswick, New Jersey
|
|
08933
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Title of each class
|
|
Name of each exchange on which registered
|
Common Stock, Par Value $1.00
|
|
New York Stock Exchange
|
Parts I, II and III:
|
|
Portions of registrant’s annual report to shareholders for fiscal year 2012 (the “Annual Report”).
|
Parts I and III:
|
|
Portions of registrant’s proxy statement for its 2013 annual meeting of shareholders filed within 120 days after the close of the registrant’s fiscal year (the “Proxy Statement”).
|
Item
|
|
Page
|
PART I
|
||
1
|
1
|
|
|
1
|
|
|
1
|
|
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
|
||
1A.
|
||
1B.
|
||
2
|
||
3
|
||
4
|
||
|
||
|
||
PART II
|
||
5
|
||
6
|
||
7
|
||
7A.
|
||
8
|
||
9
|
||
9A.
|
||
9B.
|
||
|
||
PART III
|
||
10
|
||
11
|
||
12
|
||
13
|
||
14
|
||
|
||
PART IV
|
||
15
|
||
|
||
|
||
|
||
|
Item 1.
|
BUSINESS
|
Item 1B.
|
UNRESOLVED STAFF COMMENTS
|
Item 2.
|
PROPERTIES
|
Segment
|
|
Square Feet
(in thousands)
|
|
Consumer
|
|
7,335
|
|
Pharmaceutical
|
|
7,061
|
|
Medical Devices and Diagnostics
|
|
7,248
|
|
Worldwide Total
|
|
21,644
|
|
Geographic Area
|
|
Number of Facilities
|
|
Square Feet
(in thousands)
|
||
United States
|
|
51
|
|
|
6,346
|
|
Europe
|
|
43
|
|
|
7,937
|
|
Western Hemisphere, excluding U.S.
|
|
17
|
|
|
3,465
|
|
Africa, Asia and Pacific
|
|
35
|
|
|
3,896
|
|
Worldwide Total
|
|
146
|
|
|
21,644
|
|
Item 3.
|
LEGAL PROCEEDINGS
|
Item 4.
|
Name
|
|
Age
|
|
Position
|
Dominic J. Caruso
|
|
55
|
|
Member, Executive Committee; Vice President, Finance; Chief Financial Officer(a)
|
Peter M. Fasolo
|
|
50
|
|
Member, Executive Committee; Vice President, Global Human Resources (b)
|
Alex Gorsky
|
|
52
|
|
Chairman, Board of Directors; Chairman, Executive Committee; Chief Executive Officer
|
Sandra E. Peterson
|
|
54
|
|
Member, Executive Committee; Group Worldwide Chairman(c)
|
Paulus Stoffels
|
|
51
|
|
Member, Executive Committee; Chief Scientific Officer; Worldwide Chairman, Pharmaceuticals Group(d)
|
Michael H. Ullmann
|
|
54
|
|
Member, Executive Committee; Vice President, General Counsel(e)
|
(a)
|
Mr. D. J. Caruso joined the Company in 1999 when the Company acquired Centocor, Inc. At the time of that acquisition, he had been Senior Vice President, Finance of Centocor. Mr. Caruso was named Vice President, Finance of Ortho-McNeil Pharmaceutical, Inc., a subsidiary of the Company, in 2001 and Vice President, Group Finance of the Company’s Medical Devices and Diagnostics Group in 2003. In 2005, Mr. Caruso was named Vice President of the Company’s Group Finance organization. Mr. Caruso became a Member of the Executive Committee and Vice President, Finance and Chief Financial Officer in 2007.
|
(b)
|
Dr. P. M. Fasolo joined the Company in 2004 as Vice President, Worldwide Human Resources for Cordis Corporation, a subsidiary of the Company. He was then named Vice President, Global Talent Management for the Company. He left Johnson & Johnson in 2007 to join Kohlberg Kravis Roberts & Co. as Chief Talent Officer. Dr. Fasolo returned to the Company in September 2010 as the Vice President, Global Human Resources, and in January 2011, he became a Member of the Executive Committee.
|
(c)
|
Ms. S. E. Peterson joined the Company in December 2012 as Group Worldwide Chairman and a Member of the Executive Committee, with responsibility for the Consumer Group of Companies, Johnson & Johnson Supply Chain, and Information Technology. Prior to joining Johnson & Johnson, Ms. Peterson had an extensive global career in healthcare, consumer goods and consulting. Most recently, she was Chairman and Chief Executive Officer of Bayer
|
(d)
|
Dr. P. Stoffels joined the Company in 2002 with the acquisition of Virco and Tibotec, where he was Chief Executive Officer of Virco and Chairman of Tibotec. In 2005, he was appointed Company Group Chairman, Global Virology where he led the development of PREZISTA® and INTELENCE®, leading products for the treatment of HIV. In 2006, he assumed the role of Company Group Chairman, Pharmaceuticals, with responsibility for worldwide research and development for the CNS and Internal Medicine Franchises. Dr. Stoffels was appointed Global Head, Research & Development, Pharmaceuticals, in 2009, and in 2011 became Worldwide Chairman, Pharmaceuticals Group, with responsibility for research and development, business development and global strategy and innovation. In October 2012, Dr. Stoffels was appointed Chief Scientific Officer and a Member of the Executive Committee.
|
(e)
|
Mr. M. H. Ullmann joined the Company in 1989 as a corporate attorney in the Law Department. He was appointed Corporate Secretary in 1999 and served in that role until 2006. During that time, he also held various management positions in the Law Department. In 2006, he was named General Counsel of the Medical Devices and Diagnostics Group. Mr. Ullmann was appointed Vice President, General Counsel and a Member of the Executive Committee in January 2012.
|
Item 5.
|
MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
|
Period
|
|
Total Number
of Shares Purchased
|
|
Avg. Price
Paid Per Share
|
|
Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs
|
|
Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs
|
|||
October 1, 2012 through October 28, 2012
|
|
126,488
|
|
|
$
|
70.62
|
|
|
-
|
|
-
|
October 29, 2012 through November 25, 2012
|
|
58,338
|
|
|
71.49
|
|
|
-
|
|
-
|
|
November 26, 2012 through December 30, 2012
|
|
139,288
|
|
|
70.44
|
|
|
-
|
|
-
|
|
Total
|
|
324,114
|
|
|
|
|
|
|
|
Item 6.
|
SELECTED FINANCIAL DATA
|
Item 7.
|
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
Item 7A.
|
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
Item 8.
|
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
|
Item 9.
|
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
|
Item 9A.
|
CONTROLS AND PROCEDURES
|
Item 9B.
|
OTHER INFORMATION
|
Item 10.
|
DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
|
Item 11.
|
EXECUTIVE COMPENSATION
|
Item 12.
|
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
|
Plan Category
|
Number of Securities to
be Issued Upon Exercise of
Outstanding Options and Rights
|
|
Weighted Average
Exercise Price of
Outstanding Options and Rights
|
|
Number of Securities
Remaining Available for
Future Issuance Under Equity Compensation Plans(3)(4)
|
||||
Equity Compensation Plans Approved by Security Holders
(1)
|
166,461,456
|
|
|
|
$49.70
|
|
|
201,764,610
|
|
Equity Compensation Plans Not Approved by Security Holders
(2)(3)
|
7,774
|
|
|
|
$54.69
|
|
|
—
|
|
Total
|
166,469,230
|
|
|
|
$49.70
|
|
|
201,764,610
|
|
(1)
|
Included in this category are the following equity compensation plans, which have been approved by the Company’s shareholders: 2000 Stock Option Plan, 2005 Long-Term Incentive Plan and 2012 Long-Term Incentive Plan.
|
(2)
|
Included in this category are 7,774 shares of Common Stock of the Company issuable under one equity compensation plan assumed by the Company upon acquisition of Scios, Inc. At the time of the acquisition, options to acquire equity of the acquired company were replaced by options to acquire the Common Stock of the Company. No stock options or equity awards of any type have been made under this plan since the assumption of the plan by the Company, and no further stock options or other equity awards of any type will be made under this plan in the future.
|
(3)
|
This column excludes shares reflected under the column “Number of Securities to be Issued Upon Exercise of Outstanding Options and Rights.”
|
(4)
|
The 2005 Long-Term Incentive Plan expired April 26, 2012. All options and restricted shares granted subsequent to that date were under the 2012 Long-Term Incentive Plan.
|
Item 13.
|
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
|
Item 14.
|
PRINCIPAL ACCOUNTANT FEES AND SERVICES
|
Item 15.
|
EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
|
|
Balance at
Beginning of
Period
|
|
Accruals
|
|
Payments/Other
|
|
Balance at
End of
Period
|
|||||
2012
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued Rebates
(1)
|
$
|
2,215
|
|
|
8,973
|
|
|
(8,722
|
)
|
|
2,466
|
|
Accrued Returns
|
682
|
|
|
549
|
|
|
(521
|
)
|
|
710
|
|
|
Accrued Promotions
|
396
|
|
|
1,583
|
|
|
(1,544
|
)
|
|
435
|
|
|
Subtotal
|
$
|
3,293
|
|
|
11,105
|
|
|
(10,787
|
)
|
|
3,611
|
|
Reserve for doubtful accounts
|
361
|
|
|
127
|
|
|
(22
|
)
|
|
466
|
|
|
Reserve for cash discounts
|
99
|
|
|
1,010
|
|
|
(1,004
|
)
|
|
105
|
|
|
Total
|
$
|
3,753
|
|
|
12,242
|
|
|
(11,813
|
)
|
|
4,182
|
|
2011
|
|
|
|
|
|
|
|
|||||
Accrued Rebates
(1)
|
$
|
2,146
|
|
|
8,331
|
|
|
(8,262
|
)
|
|
2,215
|
|
Accrued Returns
|
640
|
|
|
560
|
|
|
(518
|
)
|
|
682
|
|
|
Accrued Promotions
|
427
|
|
|
1,774
|
|
|
(1,805
|
)
|
|
396
|
|
|
Subtotal
|
$
|
3,213
|
|
|
10,665
|
|
|
(10,585
|
)
|
|
3,293
|
|
Reserve for doubtful accounts
|
340
|
|
|
77
|
|
|
(56
|
)
|
|
361
|
|
|
Reserve for cash discounts
|
110
|
|
|
960
|
|
|
(971
|
)
|
|
99
|
|
|
Total
|
$
|
3,663
|
|
|
11,702
|
|
|
(11,612
|
)
|
|
3,753
|
|
2010
|
|
|
|
|
|
|
|
|||||
Accrued Rebates
(1)
|
$
|
1,639
|
|
|
8,400
|
|
|
(7,893
|
)
|
|
2,146
|
|
Accrued Returns
|
689
|
|
|
517
|
|
|
(566
|
)
|
|
640
|
|
|
Accrued Promotions
|
429
|
|
|
2,664
|
|
|
(2,666
|
)
|
|
427
|
|
|
Subtotal
|
$
|
2,757
|
|
|
11,581
|
|
|
(11,125
|
)
|
|
3,213
|
|
Reserve for doubtful accounts
|
333
|
|
|
130
|
|
|
(123
|
)
|
|
340
|
|
|
Reserve for cash discounts
|
101
|
|
|
1,112
|
|
|
(1,103
|
)
|
|
110
|
|
|
Total
|
$
|
3,191
|
|
|
12,823
|
|
|
(12,351
|
)
|
|
3,663
|
|
(1)
|
Includes reserve for customer rebates of $642 million, $656 million and $701 million at December 30, 2012, January 1, 2012 and January 2, 2011, respectively.
|
JOHNSON & JOHNSON
|
(Registrant)
|
By
|
/s/ A. Gorsky
|
|
A. Gorsky, Chairman, Board of Directors,
and Chief Executive Officer |
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ A. Gorsky
|
|
Chairman, Board of Directors,
|
|
February 21, 2013
|
A. Gorsky
|
|
Chief Executive Officer, and Director (Principal Executive Officer)
|
|
|
|
|
|
|
|
/s/ D. J. Caruso
|
|
Chief Financial Officer (Principal Financial Officer)
|
|
February 21, 2013
|
D. J. Caruso
|
|
|
|
|
|
|
|
|
|
/s/ S. J. Cosgrove
|
|
Controller (Principal Accounting Officer)
|
|
February 21, 2013
|
S. J. Cosgrove
|
|
|
|
|
|
|
|
|
|
/s/ M. S. Coleman
|
|
Director
|
|
February 21, 2013
|
M. S. Coleman
|
|
|
|
|
|
|
|
|
|
/s/ J. G. Cullen
|
|
Director
|
|
February 21, 2013
|
J. G. Cullen
|
|
|
|
|
|
|
|
|
|
/s/ I. E. L. Davis
|
|
Director
|
|
February 21, 2013
|
I. E. L. Davis
|
|
|
|
|
|
|
|
|
|
/s/ M. M. E. Johns
|
|
Director
|
|
February 21, 2013
|
M. M. E. Johns
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ S. L. Lindquist
|
|
Director
|
|
February 21, 2013
|
S. L. Lindquist
|
|
|
|
|
|
|
|
|
|
/s/ A. M. Mulcahy
|
|
Director
|
|
February 21, 2013
|
A. M. Mulcahy
|
|
|
|
|
|
|
|
|
|
/s/ L. F. Mullin
|
|
Director
|
|
February 21, 2013
|
L. F. Mullin
|
|
|
|
|
|
|
|
|
|
/s/ W. D. Perez
|
|
Director
|
|
February 21, 2013
|
W. D. Perez
|
|
|
|
|
|
|
|
|
|
/s/ C. Prince
|
|
Director
|
|
February 21, 2013
|
C. Prince
|
|
|
|
|
|
|
|
|
|
/s/ D. Satcher
|
|
Director
|
|
February 21, 2013
|
D. Satcher
|
|
|
|
|
|
|
|
|
|
/s/ A. E. Washington
|
|
Director
|
|
February 21, 2013
|
A. E. Washington
|
|
|
|
|
|
|
|
|
|
/s/ R. A. Williams
|
|
Director
|
|
February 21, 2013
|
R. A. Williams
|
|
|
|
|
Reg. S-K
|
|
|
Exhibit Table
|
|
Description
|
Item No.
|
|
of Exhibit
|
3(i)(a)
|
|
Restated Certificate of Incorporation effective April 26, 1990 — Incorporated herein by reference to Exhibit 3(a) of the Registrant’s Form 10-K Annual Report for the year ended December 30, 1990.
|
3(i)(b)
|
|
Certificate of Amendment to the Restated Certificate of Incorporation of the Company effective May 20, 1992 — Incorporated herein by reference to Exhibit 3(a) of the Registrant’s Form 10-K Annual Report for the year ended January 3, 1993.
|
3(i)(c)
|
|
Certificate of Amendment to the Restated Certificate of Incorporation of the Company effective May 21, 1996 — Incorporated herein by reference to Exhibit 3(a)(iii) of the Registrant’s Form 10-K Annual Report for the year ended December 29, 1996.
|
3(i)(d)
|
|
Certificate of Amendment to the Restated Certificate of Incorporation of the Company effective May 22, 2001 — Incorporated herein by reference to Exhibit 3 of the Registrant’s Form 10-Q Quarterly Report for the quarter ended July 1, 2001.
|
3(i)(e)
|
|
Certificate of Amendment to the Restated Certificate of Incorporation of the Company effective April 27, 2006 — Incorporated herein by reference to Exhibit 3(i) of the Registrant’s Form 10-Q Quarterly Report for the quarter ended April 2, 2006.
|
3(ii)
|
|
By-Laws of the Company, as amended effective April 17, 2012 — Incorporated herein by reference to Exhibit 3.1 the Registrant’s Form 8-K Current Report filed April 19, 2012.
|
4(a)
|
|
Upon the request of the Securities and Exchange Commission, the Registrant will furnish a copy of all instruments defining the rights of holders of long-term debt of the Registrant.
|
10(a)
|
|
Stock Option Plan for Non-Employee Directors — Incorporated herein by reference to Exhibit 10(a) of the Registrant’s Form 10-K Annual Report for the year ended December 29, 1996.*
|
10(b)
|
|
2000 Stock Option Plan (as amended) — Incorporated herein by reference to Exhibit 10(b) of the Registrant's Form 10-K Annual Report for the year ended January 1, 2012.*
|
10(c)
|
|
2005 Long-Term Incentive Plan — Incorporated herein by reference to Exhibit 4 of the Registrant’s S-8 Registration Statement filed with the Commission on May 10, 2005 (file no. 333-124785).*
|
10(d)
|
|
Form of Restricted Shares to Non-Employee Directors under the 2005 Long-Term Incentive Plan — Incorporated herein by reference to Exhibit 10.1 of the Registrant’s Form 8-K Current Report filed August 25, 2005.*
|
10(e)
|
|
Form of Stock Option Certificate, Restricted Share Unit Certificate and Performance Share Unit Certificate under the 2005 Long-Term Incentive Plan — Incorporated herein by reference to Exhibits 10.1, 10.2 and 10.3 of the Registrant’s Form 8-K Current Report filed January 13, 2012.*
|
10(f)
|
|
2012 Long-Term Incentive Plan — Incorporated herein by reference to Appendix A of the Registrant’s Proxy Statement filed with the Commission on March 14, 2012 .*
|
10(g)
|
|
Form of Stock Option Certificate, Restricted Share Unit Certificate and Performance Share Unit Certificate under the 2012 Long-Term Incentive Plan — Incorporated herein by reference to Exhibits 10.2, 10.3 and 10.4 of the Registrant’s Form 10-Q Quarterly Report filed May 7, 2012.*
|
10(h)
|
|
Executive Incentive Plan (as amended) — Incorporated herein by reference to Exhibit 10(f) of the Registrant’s Form 10-K Annual Report for the year ended December 31, 2000.*
|
10(i)
|
|
Domestic Deferred Compensation (Certificate of Extra Compensation) Plan — Incorporated herein by reference to Exhibit 10(g) of the Registrant’s Form 10-K Annual Report for the year ended December 28, 2003.*
|
10(j)
|
|
Amendments to the Certificate of Extra Compensation Plan effective as of January 1, 2009 — Incorporated herein by reference to Exhibit 10(j) of the Registrant’s Form 10-K Annual Report for the year ended December 28, 2008.*
|
10(k)
|
|
2009 Certificates of Long-Term Performance Plan — Incorporated herein by reference to Exhibit 10.1 of the Registrant’s Form 10-Q Quarterly Report for the quarter ended September 27, 2009.*
|
10(l)
|
|
Amended and Restated Deferred Fee Plan for Directors — Incorporated herein by reference to Exhibit 10(k) of the Registrant's Form 10-K Annual Report for the year ended January 1, 2012.*
|
10(m)
|
|
Executive Income Deferral Plan (Amended and Restated) — Incorporated herein by reference to Exhibit 10.1 of the Registrant’s Form 10-Q Quarterly Report for the quarter ended September 30, 2012.*
|
Reg. S-K
|
|
|
Exhibit Table
|
|
Description
|
Item No.
|
|
of Exhibit
|
10(n)
|
|
Excess Savings Plan — Incorporated herein by reference to Exhibit 10(j) of the Registrant’s Form 10-K Annual Report for the year ended December 29, 1996.*
|
10(o)
|
|
Amendments to the Johnson & Johnson Excess Savings Plan effective as of January 1, 2009 — Incorporated herein by reference to Exhibit 10(p) of the Registrant’s Form 10-K Annual Report for the year ended December 28, 2008.*
|
10(p)
|
|
Excess Benefit Plan (Supplemental Retirement Plan) — Incorporated herein by reference to Exhibit 10(h) of the Registrant’s Form 10-K Annual Report for the year ended January 3, 1993.*
|
10(q)
|
|
Amendments to the Excess Benefit Plan of Johnson & Johnson and Affiliated Companies effective as of January 1, 2009 — Incorporated herein by reference to Exhibit 10(r) of the Registrant’s Form 10-K Annual Report for the year ended December 28, 2008.*
|
10(r)
|
|
Executive Life Plan Agreement — Incorporated herein by reference to Exhibit 10(i) of the Registrant’s Form 10-K Annual Report for the year ended January 3, 1993.*
|
10(s)
|
|
Employment Agreement for Dr. Paulus Stoffels - Incorporated herein by reference to Exhibit 10.2 of the Registrant’s Form 10-Q Quarterly Report for the quarter ended September 30, 2012.*
|
10(t)
|
|
Summary of Employment Arrangements for Sandra E. Peterson — Filed with this document.*
|
12
|
|
Statement of Computation of Ratio of Earnings to Fixed Charges — Filed with this document.
|
13
|
|
The following sections of the Annual Report to Shareholders for fiscal year 2012, which are incorporated by reference in this report, are deemed “filed”: “Management's Discussion and Analysis of Results of Operations and Financial Condition”; “Audited Consolidated Financial Statements”; “Supporting Schedules - Summary of Operations and Statistical Data 2002 - 2012”; and “Supporting Schedules - Shareholder Return Performance Graphs” - Filed with this document.
|
21
|
|
Subsidiaries — Filed with this document.
|
23
|
|
Consent of Independent Registered Public Accounting Firm — Filed with this document.
|
31(a)
|
|
Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act — Filed with this document.
|
31(b)
|
|
Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act — Filed with this document.
|
32(a)
|
|
Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act — Furnished with this document.
|
32(b)
|
|
Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act — Furnished with this document.
|
99
|
|
Cautionary Statement Pursuant to Private Securities Litigation Reform Act of 1995 — “Safe Harbor” for Forward-Looking Statements — Filed with this document.
|
101
|
|
XBRL (Extensible Business Reporting Language) The following materials from Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year-ended December 30, 2012, formatted in Extensive Business Reporting Language (XBRL): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Earnings, (iii) Consolidated Statements of Comprehensive Income, (iv) Consolidated Statements of Equity, (v) Consolidated Statements of Cash Flows, (vi) Notes to the Consolidated Financial Statements, and (vii) Schedule II — Valuation and Qualifying Accounts.
|
*
|
Management contract or compensatory plan.
|
A)
|
the Employer, a corporation organized under the laws of the State of New Jersey in the United States of America, wishes to hire Employee for an indefinite term; and
|
B)
|
the Employee desires to work for the Employer.
|
1.
|
TITLE, JOB DUTIES AND REPORTING RELATIONSHIP
|
2.
|
WORK LOCATION
|
3.
|
EMPLOYMENT TERMS AND START DATE
|
4.
|
SALARY
|
5.
|
SIGN-ON BONUS
|
6.
|
RSU REPLACEMENT AWARD
|
7.
|
SEVERANCE
|
8.
|
DISCRETIONARY BONUS AND OTHER REMUNERATION
|
9.
|
COMPENSATION GENERALLY
|
10.
|
BENEFIT PROGRAMS
|
11.
|
EXPENSES
|
12.
|
VACATION
|
13.
|
RELOCATION
|
14.
|
CONFIDENTIALITY, NON-COMPETITION AND NON-SOLICITATION
|
15.
|
EMPLOYMENT APPLICATION AND OTHER PRE-EMPLOYMENT FORMS
|
16.
|
ASSIGNMENT
|
17.
|
COMMON GROUND PROGRAM
|
18.
|
MISCELLANEOUS
|
19.
|
APPLICABLE LAW
|
20.
|
ADDENDUMS
|
21.
|
EFFECTIVE DATE OF THIS AGREEMENT
|
DATED: August 14, 2012
|
EMPLOYER - Johnson & Johnson
By
/s/ Peter M. Fasolo
Peter M. Fasolo
Worldwide Vice-President, Human Resources
|
DATED: August 29, 2012
|
EMPLOYEE - Sandra E. Peterson
By
/s/ Sandra E. Peterson
Sandra E. Peterson
|
|
|
|
Fiscal Year Ended
|
||||||||||||||||||
|
December 30, 2012
|
|
January 1, 2012
|
|
January 2,
2011
|
|
January 3,
2010
|
|
December 28,
2008
|
|
|
||||||||||
Determination of Earnings:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Earnings Before Provision for Taxes on Income
|
$
|
13,775
|
|
|
$
|
12,361
|
|
|
$
|
16,947
|
|
|
$
|
15,755
|
|
|
$
|
16,929
|
|
|
|
Fixed Charges, less Capitalized Interest
|
657
|
|
|
675
|
|
|
555
|
|
|
558
|
|
|
538
|
|
|
|
|||||
Total Earnings as Defined
|
$
|
14,432
|
|
|
$
|
13,036
|
|
|
$
|
17,502
|
|
|
$
|
16,313
|
|
|
$
|
17,467
|
|
|
|
Fixed Charges:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Estimated Interest Portion of Rent Expense
|
125
|
|
|
104
|
|
|
100
|
|
|
107
|
|
|
103
|
|
|
|
|||||
Interest Expense before Capitalization of Interest
|
647
|
|
|
655
|
|
|
528
|
|
|
552
|
|
|
583
|
|
|
|
|||||
Total Fixed Charges
|
$
|
772
|
|
|
$
|
759
|
|
|
$
|
628
|
|
|
$
|
659
|
|
|
$
|
686
|
|
|
|
Ratio of Earnings to Fixed Charges
|
18.69
|
|
|
17.18
|
|
|
27.87
|
|
|
24.75
|
|
|
25.46
|
|
|
|
(1)
|
The ratio of earnings to fixed charges is computed by dividing the sum of earnings before provision for taxes on income and fixed charges by fixed charges. Fixed charges represent interest expense (before interest is capitalized), amortization of debt discount and an appropriate interest factor on operating leases.
|
MANAGEMENT’S DISCUSSION AND ANALYSIS OF RESULTS
OF OPERATIONS AND FINANCIAL CONDITION
|
|
|
|
AUDITED CONSOLIDATED FINANCIAL STATEMENTS
|
|
|
|
SUPPORTING SCHEDULES
|
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
1
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
2
|
Sales increase/(decrease) due to:
|
|
2012
|
|
2011
|
|
2010
|
|||
Volume
|
|
5.7
|
%
|
|
3.1
|
|
|
(0.5
|
)
|
Price
|
|
0.4
|
|
|
(0.3
|
)
|
|
(0.8
|
)
|
Currency
|
|
(2.7
|
)
|
|
2.8
|
|
|
0.8
|
|
Total
|
|
3.4
|
%
|
|
5.6
|
|
|
(0.5
|
)
|
|
|
|
|
|
|
|
|
% Change
|
||||||||
(Dollars in Millions)
|
|
2012
|
|
2011
|
|
2010
|
|
’12 vs. ’11
|
|
’11 vs. ’10
|
||||||
OTC Pharmaceuticals & Nutritionals
|
|
$
|
4,354
|
|
|
4,402
|
|
|
4,549
|
|
|
(1.1
|
)%
|
|
(3.2
|
)
|
Skin Care
|
|
3,618
|
|
|
3,715
|
|
|
3,452
|
|
|
(2.6
|
)
|
|
7.6
|
|
|
Baby Care
|
|
2,254
|
|
|
2,340
|
|
|
2,209
|
|
|
(3.7
|
)
|
|
5.9
|
|
|
Women’s Health
|
|
1,625
|
|
|
1,792
|
|
|
1,844
|
|
|
(9.3
|
)
|
|
(2.8
|
)
|
|
Oral Care
|
|
1,624
|
|
|
1,624
|
|
|
1,526
|
|
|
0.0
|
|
6.4
|
|
||
Wound Care/Other
|
|
972
|
|
|
1,010
|
|
|
1,010
|
|
|
(3.8
|
)
|
|
0.0
|
|
|
Total Consumer Sales
|
|
$
|
14,447
|
|
|
14,883
|
|
|
14,590
|
|
|
(2.9
|
)%
|
|
2.0
|
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
3
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
4
|
|
|
|
|
|
|
|
|
% Change
|
||||||||
(Dollars in Millions)
|
|
2012
|
|
2011
|
|
2010
|
|
’12 vs. ’11
|
|
’11 vs. ’10
|
||||||
Total Immunology
|
|
$
|
7,874
|
|
|
6,798
|
|
|
5,398
|
|
|
15.8
|
%
|
|
25.9
|
|
REMICADE
®
|
|
6,139
|
|
|
5,492
|
|
|
4,610
|
|
|
11.8
|
|
|
19.1
|
|
|
SIMPONI
®
|
|
607
|
|
|
410
|
|
|
226
|
|
|
48.0
|
|
|
81.4
|
|
|
STELARA
®
|
|
1,025
|
|
|
738
|
|
|
393
|
|
|
38.9
|
|
|
87.8
|
|
|
Other Immunology
|
|
103
|
|
|
158
|
|
|
169
|
|
|
(34.8
|
)
|
|
(6.5
|
)
|
|
Total Infectious Diseases
|
|
3,194
|
|
|
3,189
|
|
|
3,033
|
|
|
0.2
|
|
|
5.1
|
|
|
INTELENCE
®
|
|
349
|
|
|
314
|
|
|
243
|
|
|
11.1
|
|
|
29.2
|
|
|
LEVAQUIN
®
/FLOXIN
®
|
|
75
|
|
|
623
|
|
|
1,357
|
|
|
(88.0
|
)
|
|
(54.1
|
)
|
|
PREZISTA
®
|
|
1,414
|
|
|
1,211
|
|
|
857
|
|
|
16.8
|
|
|
41.3
|
|
|
Other Infectious Diseases
|
|
1,356
|
|
|
1,041
|
|
|
576
|
|
|
30.3
|
|
|
80.7
|
|
|
Total Neuroscience
|
|
6,718
|
|
|
6,948
|
|
|
6,644
|
|
|
(3.3
|
)
|
|
4.6
|
|
|
CONCERTA
®
/methylphenidate
|
|
1,073
|
|
|
1,268
|
|
|
1,319
|
|
|
(15.4
|
)
|
|
(3.9
|
)
|
|
INVEGA
®
|
|
550
|
|
|
499
|
|
|
424
|
|
|
10.2
|
|
|
17.7
|
|
|
INVEGA
®
SUSTENNA
®
/XEPLION
®
|
|
796
|
|
|
378
|
|
|
152
|
|
|
**
|
|
**
|
|||
RISPERDAL
®
CONSTA
®
|
|
1,425
|
|
|
1,583
|
|
|
1,500
|
|
|
(10.0
|
)
|
|
5.5
|
|
|
Other Neuroscience
|
|
2,874
|
|
|
3,220
|
|
|
3,249
|
|
|
(10.7
|
)
|
|
(0.9
|
)
|
|
Total Oncology
|
|
2,629
|
|
|
2,048
|
|
|
1,465
|
|
|
28.4
|
|
|
39.8
|
|
|
DOXIL
®
/CAELYX
®
|
|
83
|
|
|
402
|
|
|
320
|
|
|
(79.4
|
)
|
|
25.6
|
|
|
VELCADE
®
|
|
1,500
|
|
|
1,274
|
|
|
1,080
|
|
|
17.7
|
|
|
18.0
|
|
|
ZYTIGA
®
|
|
961
|
|
|
301
|
|
|
—
|
|
|
**
|
|
100.0
|
|
||
Other Oncology
|
|
85
|
|
|
71
|
|
|
65
|
|
|
19.7
|
|
|
9.2
|
|
|
Total Other
|
|
4,936
|
|
|
5,385
|
|
|
5,856
|
|
|
(8.3
|
)
|
|
(8.0
|
)
|
|
ACIPHEX
®
/PARIET
®
|
|
835
|
|
|
975
|
|
|
1,006
|
|
|
(14.4
|
)
|
|
(3.1
|
)
|
|
PROCRIT
®
/EPREX
®
|
|
1,462
|
|
|
1,623
|
|
|
1,934
|
|
|
(9.9
|
)
|
|
(16.1
|
)
|
|
Other
|
|
2,639
|
|
|
2,787
|
|
|
2,916
|
|
|
(5.3
|
)
|
|
(4.4
|
)
|
|
Total Pharmaceutical Sales
|
|
$
|
25,351
|
|
|
24,368
|
|
|
22,396
|
|
|
4.0
|
%
|
|
8.8
|
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
5
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
6
|
|
|
|
|
|
|
|
|
% Change
|
||||||||
(Dollars in Millions)
|
|
2012
|
|
2011
|
|
2010
|
|
’12 vs. ’11
|
|
’11 vs. ’10
|
||||||
Orthopaedics
|
|
$
|
7,799
|
|
|
5,809
|
|
|
5,585
|
|
|
34.3
|
%
|
|
4.0
|
|
Surgical Care
|
|
6,483
|
|
|
6,637
|
|
|
6,272
|
|
|
(2.3
|
)
|
|
5.8
|
|
|
Vision Care
|
|
2,996
|
|
|
2,916
|
|
|
2,680
|
|
|
2.7
|
|
|
8.8
|
|
|
Diabetes Care
|
|
2,616
|
|
|
2,652
|
|
|
2,470
|
|
|
(1.4
|
)
|
|
7.4
|
|
|
Specialty Surgery
|
|
2,526
|
|
|
2,407
|
|
|
2,186
|
|
|
4.9
|
|
|
10.1
|
|
|
Diagnostics
|
|
2,069
|
|
|
2,164
|
|
|
2,053
|
|
|
(4.4
|
)
|
|
5.4
|
|
|
Cardiovascular Care
|
|
1,985
|
|
|
2,288
|
|
|
2,552
|
|
|
(13.2
|
)
|
|
(10.3
|
)
|
|
Infection Prevention/Other
|
|
952
|
|
|
906
|
|
|
803
|
|
|
5.1
|
|
|
12.8
|
|
|
Total Medical Devices and Diagnostics Sales
|
|
$
|
27,426
|
|
|
25,779
|
|
|
24,601
|
|
|
6.4
|
%
|
|
4.8
|
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
7
|
% of Sales
|
|
2012
|
|
2011
|
|
2010
|
|||
Cost of products sold
|
|
32.2
|
%
|
|
31.3
|
|
|
30.5
|
|
Percent point increase over the prior year
|
|
0.9
|
|
|
0.8
|
|
|
0.7
|
|
Selling, marketing and administrative expenses
|
|
31.0
|
|
|
32.3
|
|
|
31.5
|
|
Percent point (decrease)/increase over the prior year
|
|
(1.3
|
)
|
|
0.8
|
|
|
(0.5
|
)
|
|
|
2012
|
|
2011
|
|
2010
|
|||||||||||||
(Dollars in Millions)
|
|
Amount
|
|
% of Sales*
|
|
Amount
|
|
% of Sales*
|
|
Amount
|
|
% of Sales*
|
|||||||
Consumer
|
|
$
|
622
|
|
|
4.3
|
%
|
|
659
|
|
|
4.4
|
|
|
609
|
|
|
4.2
|
|
Pharmaceutical
|
|
5,362
|
|
|
21.2
|
|
|
5,138
|
|
|
21.1
|
|
|
4,432
|
|
|
19.8
|
|
|
Medical Devices and Diagnostics
|
|
1,681
|
|
|
6.1
|
|
|
1,751
|
|
|
6.8
|
|
|
1,803
|
|
|
7.3
|
|
|
Total research and development expense
|
|
$
|
7,665
|
|
|
11.4
|
%
|
|
7,548
|
|
|
11.6
|
|
|
6,844
|
|
|
11.1
|
|
Percent increase/(decrease) over the prior year
|
|
1.6
|
%
|
|
|
|
|
10.3
|
|
|
|
|
|
(2.0
|
)
|
|
|
|
*
|
As a percent to segment sales
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
8
|
|
|
|
|
|
|
Percent of Segment Sales
|
||||||
(Dollars in Millions)
|
|
2012
|
|
2011
|
|
2012
|
|
2011
|
||||
Consumer
|
|
$
|
1,693
|
|
|
2,096
|
|
|
11.7
|
%
|
|
14.1
|
Pharmaceutical
|
|
6,075
|
|
|
6,406
|
|
|
24.0
|
|
|
26.3
|
|
Medical Devices and Diagnostics
|
|
7,187
|
|
|
5,263
|
|
|
26.2
|
|
|
20.4
|
|
Total
(1)
|
|
14,955
|
|
|
13,765
|
|
|
22.2
|
|
|
21.2
|
|
Less: Expenses not allocated to segments
(2)
|
|
1,180
|
|
|
1,404
|
|
|
|
|
|
|
|
Earnings before provision for taxes on income
|
|
$
|
13,775
|
|
|
12,361
|
|
|
20.5
|
%
|
|
19.0
|
(1)
|
See Note 18 to the Consolidated Financial Statements for more details.
|
(2)
|
Amounts not allocated to segments include interest (income) expense, noncontrolling interests, and general corporate (income) expense. A $0.2 billion and $0.5 billion currency related expense for the acquisition of Synthes, Inc. was included in 2012 and 2011, respectively.
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
9
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
10
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
11
|
(Dollars in Millions)
|
|
Long-Term
Debt Obligations |
|
Interest on
Debt Obligations |
|
Unfunded
Retirement Plans |
|
Operating Leases
|
|
Total
|
||||||
2013
|
|
$
|
1,512
|
|
|
497
|
|
|
68
|
|
|
251
|
|
|
2,328
|
|
2014
|
|
1,789
|
|
|
483
|
|
|
66
|
|
|
192
|
|
|
2,530
|
|
|
2015
|
|
—
|
|
|
477
|
|
|
71
|
|
|
149
|
|
|
697
|
|
|
2016
|
|
898
|
|
|
471
|
|
|
76
|
|
|
115
|
|
|
1,560
|
|
|
2017
|
|
1,000
|
|
|
436
|
|
|
80
|
|
|
90
|
|
|
1,606
|
|
|
After 2017
|
|
7,802
|
|
|
4,232
|
|
|
502
|
|
|
128
|
|
|
12,664
|
|
|
Total
|
|
$
|
13,001
|
|
|
6,596
|
|
|
863
|
|
|
925
|
|
|
21,385
|
|
|
2012
|
|
2011
|
|
2010
|
||||
First quarter
|
$
|
0.57
|
|
|
0.54
|
|
|
0.49
|
|
Second quarter
|
0.61
|
|
|
0.57
|
|
|
0.54
|
|
|
Third quarter
|
0.61
|
|
|
0.57
|
|
|
0.54
|
|
|
Fourth quarter
|
0.61
|
|
|
0.57
|
|
|
0.54
|
|
|
Total
|
$
|
2.40
|
|
|
2.25
|
|
|
2.11
|
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
12
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
13
|
(Dollars in Millions)
|
|
Balance at
Beginning of Period |
|
Accruals
|
|
Payments/Credits
|
|
Balance at
End of Period |
|||||
2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued rebates
(1)
|
|
$
|
127
|
|
|
438
|
|
|
(433
|
)
|
|
132
|
|
Accrued returns
|
|
114
|
|
|
131
|
|
|
(137
|
)
|
|
108
|
|
|
Accrued promotions
|
|
240
|
|
|
1,392
|
|
|
(1,351
|
)
|
|
281
|
|
|
Subtotal
|
|
$
|
481
|
|
|
1,961
|
|
|
(1,921
|
)
|
|
521
|
|
Reserve for doubtful accounts
|
|
43
|
|
|
6
|
|
|
(11
|
)
|
|
38
|
|
|
Reserve for cash discounts
|
|
22
|
|
|
214
|
|
|
(215
|
)
|
|
21
|
|
|
Total
|
|
$
|
546
|
|
|
2,181
|
|
|
(2,147
|
)
|
|
580
|
|
|
|
|
|
|
|
|
|
|
|||||
2011
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued rebates
(1)
|
|
$
|
131
|
|
|
346
|
|
|
(350
|
)
|
|
127
|
|
Accrued returns
|
|
145
|
|
|
103
|
|
|
(134
|
)
|
|
114
|
|
|
Accrued promotions
|
|
294
|
|
|
1,520
|
|
|
(1,574
|
)
|
|
240
|
|
|
Subtotal
|
|
$
|
570
|
|
|
1,969
|
|
|
(2,058
|
)
|
|
481
|
|
Reserve for doubtful accounts
|
|
57
|
|
|
3
|
|
|
(17
|
)
|
|
43
|
|
|
Reserve for cash discounts
|
|
21
|
|
|
226
|
|
|
(225
|
)
|
|
22
|
|
|
Total
|
|
$
|
648
|
|
|
2,198
|
|
|
(2,300
|
)
|
|
546
|
|
(1)
|
Includes reserve for customer rebates of $33 million at December 30, 2012 and $34 million at January 1, 2012, recorded as a contra asset.
|
(Dollars in Millions)
|
|
Balance at
Beginning of Period |
|
Accruals
|
|
Payments/Credits
|
|
Balance at
End of Period |
|||||
2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued rebates
(1)
|
|
$
|
1,591
|
|
|
4,732
|
|
|
(4,556
|
)
|
|
1,767
|
|
Accrued returns
|
|
384
|
|
|
49
|
|
|
(36
|
)
|
|
397
|
|
|
Accrued promotions
|
|
83
|
|
|
142
|
|
|
(131
|
)
|
|
94
|
|
|
Subtotal
|
|
$
|
2,058
|
|
|
4,923
|
|
|
(4,723
|
)
|
|
2,258
|
|
Reserve for doubtful accounts
|
|
157
|
|
|
47
|
|
|
(13
|
)
|
|
191
|
|
|
Reserve for cash discounts
|
|
45
|
|
|
425
|
|
|
(408
|
)
|
|
62
|
|
|
Total
|
|
$
|
2,260
|
|
|
5,395
|
|
|
(5,144
|
)
|
|
2,511
|
|
|
|
|
|
|
|
|
|
|
|||||
2011
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued rebates
(1)
|
|
$
|
1,520
|
|
|
4,732
|
|
|
(4,661
|
)
|
|
1,591
|
|
Accrued returns
|
|
294
|
|
|
105
|
|
|
(15
|
)
|
|
384
|
|
|
Accrued promotions
|
|
83
|
|
|
187
|
|
|
(187
|
)
|
|
83
|
|
|
Subtotal
|
|
$
|
1,897
|
|
|
5,024
|
|
|
(4,863
|
)
|
|
2,058
|
|
Reserve for doubtful accounts
|
|
145
|
|
|
20
|
|
|
(8
|
)
|
|
157
|
|
|
Reserve for cash discounts
|
|
54
|
|
|
392
|
|
|
(401
|
)
|
|
45
|
|
|
Total
|
|
$
|
2,096
|
|
|
5,436
|
|
|
(5,272
|
)
|
|
2,260
|
|
(1)
|
Includes reserve for customer rebates of $269 million at December 30, 2012 and $298 million at January 1, 2012, recorded as a contra asset.
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
14
|
(Dollars in Millions)
|
|
Balance at
Beginning of Period |
|
Accruals
|
|
Payments/Credits
|
|
Balance at
End of Period |
|||||
2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued rebates
(
1)
|
|
$
|
497
|
|
|
3,803
|
|
|
(3,733
|
)
|
|
567
|
|
Accrued returns
|
|
184
|
|
|
369
|
|
|
(348
|
)
|
|
205
|
|
|
Accrued promotions
|
|
73
|
|
|
49
|
|
|
(62
|
)
|
|
60
|
|
|
Subtotal
|
|
$
|
754
|
|
|
4,221
|
|
|
(4,143
|
)
|
|
832
|
|
Reserve for doubtful accounts
|
|
161
|
|
|
74
|
|
|
2
|
|
|
237
|
|
|
Reserve for cash discounts
|
|
32
|
|
|
371
|
|
|
(381
|
)
|
|
22
|
|
|
Total
|
|
$
|
947
|
|
|
4,666
|
|
|
(4,522
|
)
|
|
1,091
|
|
|
|
|
|
|
|
|
|
|
|||||
2011
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued rebates
(1)
|
|
$
|
495
|
|
|
3,253
|
|
|
(3,251
|
)
|
|
497
|
|
Accrued returns
|
|
201
|
|
|
352
|
|
|
(369
|
)
|
|
184
|
|
|
Accrued promotions
|
|
50
|
|
|
67
|
|
|
(44
|
)
|
|
73
|
|
|
Subtotal
|
|
$
|
746
|
|
|
3,672
|
|
|
(3,664
|
)
|
|
754
|
|
Reserve for doubtful accounts
|
|
138
|
|
|
54
|
|
|
(31
|
)
|
|
161
|
|
|
Reserve for cash discounts
|
|
35
|
|
|
342
|
|
|
(345
|
)
|
|
32
|
|
|
Total
|
|
$
|
919
|
|
|
4,068
|
|
|
(4,040
|
)
|
|
947
|
|
(1)
|
Includes reserve for customer rebates of $340 million at December 30, 2012 and $324 million at January 1, 2012, recorded as a contra asset.
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
15
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
16
|
|
2012
|
|
2011
|
|||||||||
|
High
|
|
Low
|
|
High
|
|
Low
|
|||||
First quarter
|
$
|
66.32
|
|
|
64.02
|
|
|
63.54
|
|
|
57.50
|
|
Second quarter
|
67.70
|
|
|
61.71
|
|
|
67.37
|
|
|
59.25
|
|
|
Third quarter
|
69.75
|
|
|
66.85
|
|
|
68.05
|
|
|
59.08
|
|
|
Fourth quarter
|
72.74
|
|
|
67.80
|
|
|
66.32
|
|
|
60.83
|
|
|
Year-end close
|
$69.48
|
|
65.58
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
17
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
18
|
|
2012
|
|
2011
|
|||
Assets
|
|
|
|
|||
Current assets
|
|
|
|
|
|
|
Cash and cash equivalents (Notes 1 and 2)
|
$
|
14,911
|
|
|
24,542
|
|
Marketable securities (Notes 1 and 2)
|
6,178
|
|
|
7,719
|
|
|
Accounts receivable trade, less allowances for doubtful accounts $466 (2011, $361)
|
11,309
|
|
|
10,581
|
|
|
Inventories (Notes 1 and 3)
|
7,495
|
|
|
6,285
|
|
|
Deferred taxes on income (Note 8)
|
3,139
|
|
|
2,556
|
|
|
Prepaid expenses and other receivables
|
3,084
|
|
|
2,633
|
|
|
Total current assets
|
46,116
|
|
|
54,316
|
|
|
Property, plant and equipment, net (Notes 1 and 4)
|
16,097
|
|
|
14,739
|
|
|
Intangible assets, net (Notes 1 and 5)
|
28,752
|
|
|
18,138
|
|
|
Goodwill (Notes 1 and 5)
|
22,424
|
|
|
16,138
|
|
|
Deferred taxes on income (Note 8)
|
4,541
|
|
|
6,540
|
|
|
Other assets
|
3,417
|
|
|
3,773
|
|
|
Total assets
|
$
|
121,347
|
|
|
113,644
|
|
Liabilities and Shareholders’ Equity
|
|
|
|
|
|
|
Current liabilities
|
|
|
|
|
|
|
Loans and notes payable (Note 7)
|
$
|
4,676
|
|
|
6,658
|
|
Accounts payable
|
5,831
|
|
|
5,725
|
|
|
Accrued liabilities
|
7,299
|
|
|
4,608
|
|
|
Accrued rebates, returns and promotions
|
2,969
|
|
|
2,637
|
|
|
Accrued compensation and employee related obligations
|
2,423
|
|
|
2,329
|
|
|
Accrued taxes on income
|
1,064
|
|
|
854
|
|
|
Total current liabilities
|
24,262
|
|
|
22,811
|
|
|
Long-term debt (Note 7)
|
11,489
|
|
|
12,969
|
|
|
Deferred taxes on income (Note 8)
|
3,136
|
|
|
1,800
|
|
|
Employee related obligations (Notes 9 and 10)
|
9,082
|
|
|
8,353
|
|
|
Other liabilities
|
8,552
|
|
|
10,631
|
|
|
Total liabilities
|
56,521
|
|
|
56,564
|
|
|
Shareholders’ equity
|
|
|
|
|
|
|
Preferred stock — without par value (authorized and unissued 2,000,000 shares)
|
—
|
|
|
—
|
|
|
Common stock — par value $1.00 per share (Note 12) (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)
|
3,120
|
|
|
3,120
|
|
|
Accumulated other comprehensive income (Note 13)
|
(5,810
|
)
|
|
(5,632
|
)
|
|
Retained earnings
|
85,992
|
|
|
81,251
|
|
|
|
83,302
|
|
|
78,739
|
|
|
Less: common stock held in treasury, at cost (Note 12) (341,354,000 shares and 395,480,000 shares)
|
18,476
|
|
|
21,659
|
|
|
Total shareholders’ equity
|
64,826
|
|
|
57,080
|
|
|
Total liabilities and shareholders’ equity
|
$
|
121,347
|
|
|
113,644
|
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
19
|
|
2012
|
|
2011
|
|
2010
|
||||
Sales to customers
|
$
|
67,224
|
|
|
65,030
|
|
|
61,587
|
|
Cost of products sold
|
21,658
|
|
|
20,360
|
|
|
18,792
|
|
|
Gross profit
|
45,566
|
|
|
44,670
|
|
|
42,795
|
|
|
Selling, marketing and administrative expenses
|
20,869
|
|
|
20,969
|
|
|
19,424
|
|
|
Research and development expense
|
7,665
|
|
|
7,548
|
|
|
6,844
|
|
|
In-process research and development (Note 5)
|
1,163
|
|
|
—
|
|
|
—
|
|
|
Interest income
|
(64
|
)
|
|
(91
|
)
|
|
(107
|
)
|
|
Interest expense, net of portion capitalized (Note 4)
|
532
|
|
|
571
|
|
|
455
|
|
|
Other (income) expense, net
|
1,626
|
|
|
2,743
|
|
|
(768
|
)
|
|
Restructuring (Note 22)
|
—
|
|
|
569
|
|
|
—
|
|
|
Earnings before provision for taxes on income
|
13,775
|
|
|
12,361
|
|
|
16,947
|
|
|
Provision for taxes on income (Note 8)
|
3,261
|
|
|
2,689
|
|
|
3,613
|
|
|
Net earnings
|
10,514
|
|
|
9,672
|
|
|
13,334
|
|
|
Add: Net loss attributable to noncontrolling interest
|
339
|
|
|
—
|
|
|
—
|
|
|
Net earnings attributable to Johnson & Johnson
|
$
|
10,853
|
|
|
9,672
|
|
|
13,334
|
|
|
|
|
|
|
|
||||
Net earnings per share attributable to Johnson & Johnson (Notes 1 and 15)
|
|
|
|
|
|
||||
Basic
|
$
|
3.94
|
|
|
3.54
|
|
|
4.85
|
|
Diluted
|
$
|
3.86
|
|
|
3.49
|
|
|
4.78
|
|
Cash dividends per share
|
$
|
2.40
|
|
|
2.25
|
|
|
2.11
|
|
Average shares outstanding (Notes 1 and 15)
|
|
|
|
|
|
||||
Basic
|
2,753.3
|
|
|
2,736.0
|
|
|
2,751.4
|
|
|
Diluted
|
2,812.6
|
|
|
2,775.3
|
|
|
2,788.8
|
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
20
|
|
2012
|
|
2011
|
|
2010
|
||||
Net Earnings
|
$
|
10,514
|
|
|
9,672
|
|
|
13,334
|
|
|
|
|
|
|
|
||||
Other Comprehensive Income (Loss), net of tax
|
|
|
|
|
|
||||
Foreign currency translation
|
1,230
|
|
|
(557
|
)
|
|
(461
|
)
|
|
|
|
|
|
|
|
||||
Securities:
|
|
|
|
|
|
||||
Unrealized holding gain (loss) arising during period
|
(248
|
)
|
|
565
|
|
|
99
|
|
|
Reclassifications to earnings
|
(5
|
)
|
|
(141
|
)
|
|
(45
|
)
|
|
Net change
|
(253
|
)
|
|
424
|
|
|
54
|
|
|
|
|
|
|
|
|
||||
Employee benefit plans:
|
|
|
|
|
|
||||
Prior service cost amortization during period
|
2
|
|
|
5
|
|
|
4
|
|
|
Prior service cost - current year
|
(8
|
)
|
|
15
|
|
|
—
|
|
|
Gain (loss) amortization during period
|
370
|
|
|
246
|
|
|
188
|
|
|
Gain (loss) - current year
|
(1,643
|
)
|
|
(1,984
|
)
|
|
(203
|
)
|
|
Effect of exchange rates
|
(52
|
)
|
|
18
|
|
|
(10
|
)
|
|
Net change
|
(1,331
|
)
|
|
(1,700
|
)
|
|
(21
|
)
|
|
|
|
|
|
|
|
||||
Derivatives & hedges:
|
|
|
|
|
|
||||
Unrealized gain (loss) arising during period
|
52
|
|
|
(500
|
)
|
|
(333
|
)
|
|
Reclassifications to earnings
|
124
|
|
|
232
|
|
|
288
|
|
|
Net change
|
176
|
|
|
(268
|
)
|
|
(45
|
)
|
|
|
|
|
|
|
|
||||
Other Comprehensive Income (Loss)
|
(178
|
)
|
|
(2,101
|
)
|
|
(473
|
)
|
|
|
|
|
|
|
|
||||
Comprehensive Income
|
$
|
10,336
|
|
|
7,571
|
|
|
12,861
|
|
|
|
|
|
|
|
||||
Comprehensive Loss Attributable To Noncontrolling Interest, net of tax
|
339
|
|
|
—
|
|
|
—
|
|
|
|
|
|
|
|
|
||||
Comprehensive Income Attributable To Johnson & Johnson
|
$
|
10,675
|
|
|
7,571
|
|
|
12,861
|
|
|
|
|
|
|
|
|
The tax effects in other comprehensive income for the fiscal years ended 2012, 2011 and 2010 respectively: Securities; $136 million, $228 million and $29 million, Employee Benefit Plans; $653 million $915 million and $11 million, Derivatives & Hedges; $95 million, $144 million and $25 million.
|
|
Foreign currency translation is not adjusted for income taxes as it relates to permanent investments in international subsidiaries.
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
21
|
|
Total
|
|
Retained
Earnings
|
|
Accumulated
Other
Comprehensive
Income
|
|
Common Stock
Issued Amount
|
|
Treasury
Stock
Amount
|
||||||
Balance, January 3, 2010
|
$
|
50,588
|
|
|
70,306
|
|
|
(3,058
|
)
|
|
3,120
|
|
|
(19,780
|
)
|
Net earnings attributable to Johnson & Johnson
|
13,334
|
|
|
13,334
|
|
|
|
|
|
|
|
|
|
|
|
Cash dividends paid
|
(5,804
|
)
|
|
(5,804
|
)
|
|
|
|
|
|
|
|
|
|
|
Employee compensation and stock option plans
|
1,731
|
|
|
(63
|
)
|
|
|
|
|
|
|
|
1,794
|
|
|
Repurchase of common stock
|
(2,797
|
)
|
|
|
|
|
|
|
|
|
|
|
(2,797
|
)
|
|
Other comprehensive income, net of tax:
|
(473
|
)
|
|
|
|
(473
|
)
|
|
|
|
|
|
|
||
Balance, January 2, 2011
|
$
|
56,579
|
|
|
77,773
|
|
|
(3,531
|
)
|
|
3,120
|
|
|
(20,783
|
)
|
Net earnings attributable to Johnson & Johnson
|
9,672
|
|
|
9,672
|
|
|
|
|
|
|
|
|
|
|
|
Cash dividends paid
|
(6,156
|
)
|
|
(6,156
|
)
|
|
|
|
|
|
|
|
|
|
|
Employee compensation and stock option plans
|
1,760
|
|
|
111
|
|
|
|
|
|
|
|
|
1,649
|
|
|
Repurchase of common stock
|
(2,525
|
)
|
|
|
|
|
|
|
|
|
|
|
(2,525
|
)
|
|
Other
|
(149
|
)
|
|
(149
|
)
|
|
|
|
|
|
|
||||
Other comprehensive income, net of tax:
|
(2,101
|
)
|
|
|
|
|
(2,101
|
)
|
|
|
|
|
|
|
|
Balance, January 1, 2012
|
$
|
57,080
|
|
|
81,251
|
|
|
(5,632
|
)
|
|
3,120
|
|
|
(21,659
|
)
|
Net earnings attributable to Johnson & Johnson
|
10,853
|
|
|
10,853
|
|
|
|
|
|
|
|
|
|
|
|
Cash dividends paid
|
(6,614
|
)
|
|
(6,614
|
)
|
|
|
|
|
|
|
|
|
|
|
Employee compensation and stock option plans
|
3,269
|
|
|
19
|
|
|
|
|
|
|
|
|
3,250
|
|
|
Issuance of common stock associated with the acquisition of Synthes, Inc.
|
13,335
|
|
|
483
|
|
|
|
|
|
|
12,852
|
|
|||
Repurchase of common stock
(1)
|
(12,919
|
)
|
|
|
|
|
|
|
|
|
|
|
(12,919
|
)
|
|
Other comprehensive income, net of tax:
|
(178
|
)
|
|
|
|
|
(178
|
)
|
|
|
|
|
|
|
|
Balance, December 30, 2012
|
$
|
64,826
|
|
|
85,992
|
|
|
(5,810
|
)
|
|
3,120
|
|
|
(18,476
|
)
|
(1)
|
Includes repurchase of common stock associated with the acquisition of Synthes, Inc.
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
22
|
|
2012
|
|
2011
|
|
2010
|
||||
Cash flows from operating activities
|
|
|
|
|
|
|
|
||
Net earnings
|
$
|
10,514
|
|
|
9,672
|
|
|
13,334
|
|
Adjustments to reconcile net earnings to cash flows from operating activities:
|
|
|
|
|
|
|
|
||
Depreciation and amortization of property and intangibles
|
3,666
|
|
|
3,158
|
|
|
2,939
|
|
|
Stock based compensation
|
662
|
|
|
621
|
|
|
614
|
|
|
Noncontrolling interest
|
339
|
|
|
—
|
|
|
—
|
|
|
Asset write-downs and impairments
|
2,131
|
|
|
160
|
|
|
—
|
|
|
Deferred tax provision
|
(39
|
)
|
|
(836
|
)
|
|
356
|
|
|
Accounts receivable allowances
|
92
|
|
|
32
|
|
|
12
|
|
|
Changes in assets and liabilities, net of effects from acquisitions:
|
|
|
|
|
|
|
|
||
Increase in accounts receivable
|
(9
|
)
|
|
(915
|
)
|
|
(207
|
)
|
|
Increase in inventories
|
(1
|
)
|
|
(715
|
)
|
|
(196
|
)
|
|
Increase in accounts payable and accrued liabilities
|
2,768
|
|
|
493
|
|
|
20
|
|
|
Increase in other current and non-current assets
|
(2,172
|
)
|
|
(1,785
|
)
|
|
(574
|
)
|
|
(Decrease)/increase in other current and non-current liabilities
|
(2,555
|
)
|
|
4,413
|
|
|
87
|
|
|
Net cash flows from operating activities
|
15,396
|
|
|
14,298
|
|
|
16,385
|
|
|
Cash flows from investing activities
|
|
|
|
|
|
|
|
||
Additions to property, plant and equipment
|
(2,934
|
)
|
|
(2,893
|
)
|
|
(2,384
|
)
|
|
Proceeds from the disposal of assets
|
1,509
|
|
|
1,342
|
|
|
524
|
|
|
Acquisitions, net of cash acquired (Note 20)
|
(4,486
|
)
|
|
(2,797
|
)
|
|
(1,269
|
)
|
|
Purchases of investments
|
(13,434
|
)
|
|
(29,882
|
)
|
|
(15,788
|
)
|
|
Sales of investments
|
14,797
|
|
|
30,396
|
|
|
11,101
|
|
|
Other (primarily intangibles)
|
38
|
|
|
(778
|
)
|
|
(38
|
)
|
|
Net cash used by investing activities
|
(4,510
|
)
|
|
(4,612
|
)
|
|
(7,854
|
)
|
|
Cash flows from financing activities
|
|
|
|
|
|
|
|||
Dividends to shareholders
|
(6,614
|
)
|
|
(6,156
|
)
|
|
(5,804
|
)
|
|
Repurchase of common stock
|
(12,919
|
)
|
|
(2,525
|
)
|
|
(2,797
|
)
|
|
Proceeds from short-term debt
|
3,268
|
|
|
9,729
|
|
|
7,874
|
|
|
Retirement of short-term debt
|
(6,175
|
)
|
|
(11,200
|
)
|
|
(6,565
|
)
|
|
Proceeds from long-term debt
|
45
|
|
|
4,470
|
|
|
1,118
|
|
|
Retirement of long-term debt
|
(804
|
)
|
|
(16
|
)
|
|
(32
|
)
|
|
Proceeds from the exercise of stock options/excess tax benefits
|
2,720
|
|
|
1,246
|
|
|
1,226
|
|
|
Other
|
(83
|
)
|
|
—
|
|
|
—
|
|
|
Net cash used by financing activities
|
(20,562
|
)
|
|
(4,452
|
)
|
|
(4,980
|
)
|
|
Effect of exchange rate changes on cash and cash equivalents
|
45
|
|
|
(47
|
)
|
|
(6
|
)
|
|
(Decrease)/increase in cash and cash equivalents
|
(9,631
|
)
|
|
5,187
|
|
|
3,545
|
|
|
Cash and cash equivalents, beginning of year (Note 1)
|
24,542
|
|
|
19,355
|
|
|
15,810
|
|
|
Cash and cash equivalents, end of year (Note 1)
|
$
|
14,911
|
|
|
24,542
|
|
|
19,355
|
|
|
|
|
|
|
|
||||
Supplemental cash flow data
|
|
|
|
|
|
|
|
|
|
Cash paid during the year for:
|
|
|
|
|
|
|
|
|
|
Interest
|
$
|
616
|
|
|
576
|
|
|
491
|
|
Income taxes
|
2,507
|
|
|
2,970
|
|
|
2,442
|
|
|
|
|
|
|
|
|
||||
Supplemental schedule of non-cash investing and financing activities
|
|
|
|
|
|
|
|
|
|
Issuance of common stock associated with the acquisition of Synthes, Inc.
|
13,335
|
|
|
—
|
|
|
—
|
|
|
Treasury stock issued for employee compensation and stock option plans, net of cash proceeds
|
615
|
|
|
433
|
|
|
673
|
|
|
Conversion of debt
|
—
|
|
|
1
|
|
|
1
|
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
23
|
|
|
|
|
|
|
||||
Acquisitions
|
|
|
|
|
|
|
|
|
|
Fair value of assets acquired
|
$
|
19,025
|
|
|
3,025
|
|
|
1,321
|
|
Fair value of liabilities assumed and noncontrolling interests
|
(1,204
|
)
|
|
(228
|
)
|
|
(52
|
)
|
|
Net fair value of acquisitions
|
$
|
17,821
|
|
|
2,797
|
|
|
1,269
|
|
Less: Issuance of common stock associated with the acquisition of Synthes, Inc.
|
13,335
|
|
|
—
|
|
|
—
|
|
|
Net cash paid for acquisitions
|
$
|
4,486
|
|
|
2,797
|
|
|
1,269
|
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
24
|
1.
|
Summary of Significant Accounting Policies
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
25
|
Building and building equipment
|
20 - 30 years
|
Land and leasehold improvements
|
10 - 20 years
|
Machinery and equipment
|
2 - 13 years
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
26
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
27
|
Nature/Type of Collaboration
|
|
Statement of Earnings Presentation
|
Third-party sale of product
|
|
Sales to customers
|
Royalties/milestones paid to collaborative partner (post-regulatory approval)*
|
|
Cost of goods sold
|
Royalties received from collaborative partner
|
|
Other income (expense), net
|
Upfront payments & milestones paid to collaborative partner (pre-regulatory approval)
|
|
Research and development expense
|
Research and development payments to collaborative partner
|
|
Research and development expense
|
Research and development payments received from collaborative partner
|
|
Reduction of Research and development expense
|
*
|
Milestones are capitalized as intangible assets and amortized to cost of goods sold over the useful life.
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
28
|
2.
|
Cash, Cash Equivalents and Current Marketable Securities
|
(Dollars in Millions)
|
|
2012
|
|
2011
|
|||
Cash
|
|
$
|
3,032
|
|
|
2,709
|
|
Government securities and obligations
|
|
15,323
|
|
|
27,017
|
|
|
Corporate debt securities
|
|
622
|
|
|
489
|
|
|
Money market funds
|
|
1,406
|
|
|
1,590
|
|
|
Time deposits
|
|
706
|
|
|
456
|
|
|
Total cash, cash equivalents and current marketable securities
|
|
$
|
21,089
|
|
|
32,261
|
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
29
|
3.
|
Inventories
|
(Dollars in Millions)
|
|
2012
|
|
2011
|
|||
Raw materials and supplies
|
|
$
|
1,416
|
|
|
1,206
|
|
Goods in process
|
|
2,262
|
|
|
1,637
|
|
|
Finished goods
|
|
3,817
|
|
|
3,442
|
|
|
Total inventories
|
|
$
|
7,495
|
|
|
6,285
|
|
4.
|
Property, Plant and Equipment
|
(Dollars in Millions)
|
|
2012
|
|
2011
|
|||
Land and land improvements
|
|
$
|
793
|
|
|
754
|
|
Buildings and building equipment
|
|
10,046
|
|
|
9,389
|
|
|
Machinery and equipment
|
|
21,075
|
|
|
19,182
|
|
|
Construction in progress
|
|
2,740
|
|
|
2,504
|
|
|
Total property, plant and equipment, gross
|
|
$
|
34,654
|
|
|
31,829
|
|
Less accumulated depreciation
|
|
18,557
|
|
|
17,090
|
|
|
Total property, plant and equipment, net
|
|
$
|
16,097
|
|
|
14,739
|
|
5.
|
Intangible Assets and Goodwill
|
(Dollars in Millions)
|
|
2012
|
|
2011
|
|||
Intangible assets with definite lives:
|
|
|
|
|
|
|
|
Patents and trademarks — gross
|
|
$
|
8,890
|
|
|
7,947
|
|
Less accumulated amortization
|
|
3,416
|
|
|
2,976
|
|
|
Patents and trademarks — net
|
|
$
|
5,474
|
|
|
4,971
|
|
Customer relationships and other intangibles — gross
|
|
$
|
18,755
|
|
|
8,716
|
|
Less accumulated amortization
|
|
4,030
|
|
|
3,432
|
|
|
Customer relationships and other intangibles — net
|
|
$
|
14,725
|
|
|
5,284
|
|
Intangible assets with indefinite lives:
|
|
|
|
|
|
|
|
Trademarks
|
|
$
|
7,648
|
|
|
6,034
|
|
Purchased in-process research and development
|
|
905
|
|
|
1,849
|
|
|
Total intangible assets with indefinite lives
|
|
$
|
8,553
|
|
|
7,883
|
|
Total intangible assets — net
|
|
$
|
28,752
|
|
|
18,138
|
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
30
|
(Dollars in Millions)
|
|
Consumer
|
|
Pharmaceuticals
|
|
Med Devices and Diagnostics
|
|
Total
|
|||||
Goodwill at January 2, 2011
|
|
$
|
8,144
|
|
|
1,225
|
|
|
5,925
|
|
|
15,294
|
|
Acquisitions
|
|
251
|
|
|
538
|
|
|
198
|
|
|
987
|
|
|
Currency translation/other
|
|
(97
|
)
|
|
(42
|
)
|
|
(4
|
)
|
|
(143
|
)
|
|
Goodwill at January 1, 2012
|
|
$
|
8,298
|
|
|
1,721
|
|
|
6,119
|
|
|
16,138
|
|
Acquisitions
|
|
10
|
|
|
46
|
|
|
6,045
|
|
|
6,101
|
|
|
Currency translation/other
|
|
211
|
|
|
25
|
|
|
(51
|
)
|
|
185
|
|
|
Goodwill at December 30, 2012
|
|
$
|
8,519
|
|
|
1,792
|
|
|
12,113
|
|
|
22,424
|
|
6.
|
Fair Value Measurements
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
31
|
(Dollars in Millions)
|
|
Gain/(Loss)
recognized in Accumulated OCI (1) |
|
Gain/(Loss) reclassified from
Accumulated OCI into income (1) |
|
Gain/(Loss) Recognized in
Other income/expense (2) |
|||||||||||||
Cash Flow Hedges by Income Statement Caption
|
|
2012
|
|
2011
|
|
2012
|
|
2011
|
|
2012
|
|
2011
|
|||||||
Sales to customers
(3)
|
|
$
|
45
|
|
|
(60
|
)
|
|
(58
|
)
|
|
(9
|
)
|
|
(1
|
)
|
|
(1
|
)
|
Cost of products sold
(3)
|
|
103
|
|
|
(103
|
)
|
|
(98
|
)
|
|
(154
|
)
|
|
(4
|
)
|
|
2
|
|
|
Research and development expense
(3)
|
|
(42
|
)
|
|
24
|
|
|
19
|
|
|
(22
|
)
|
|
(1
|
)
|
|
(1
|
)
|
|
Interest (income)/Interest expense, net
(4)
|
|
11
|
|
|
(406
|
)
|
|
(16
|
)
|
|
(45
|
)
|
|
—
|
|
|
—
|
|
|
Other (income) expense, net
(3)
|
|
(65
|
)
|
|
45
|
|
|
29
|
|
|
(2
|
)
|
|
—
|
|
|
1
|
|
|
Total
|
|
$
|
52
|
|
|
(500
|
)
|
|
(124
|
)
|
|
(232
|
)
|
|
(6
|
)
|
|
1
|
|
(1)
|
Effective portion
|
(2)
|
Ineffective portion
|
(3)
|
Foreign exchange contracts
|
(4)
|
Cross currency interest rate swaps
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
32
|
|
|
|
|
|
|
|
|
2012
|
|
2011
|
||||||
(Dollars in Millions)
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
|
Total
(1)
|
||||||
Derivatives designated as hedging instruments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign exchange contracts
|
|
$
|
—
|
|
|
423
|
|
|
—
|
|
|
423
|
|
|
442
|
|
Cross currency interest rate swaps
(2)
|
|
—
|
|
|
98
|
|
|
—
|
|
|
98
|
|
|
15
|
|
|
Total
|
|
—
|
|
|
521
|
|
|
—
|
|
|
521
|
|
|
457
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign exchange contracts
|
|
—
|
|
|
252
|
|
|
—
|
|
|
252
|
|
|
452
|
|
|
Cross currency interest rate swaps
(3)
|
|
—
|
|
|
10
|
|
|
—
|
|
|
10
|
|
|
594
|
|
|
Total
|
|
—
|
|
|
262
|
|
|
—
|
|
|
262
|
|
|
1,046
|
|
|
Derivatives not designated as hedging instruments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign exchange contracts
|
|
—
|
|
|
75
|
|
|
—
|
|
|
75
|
|
|
29
|
|
|
Swiss Franc Option
(4)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
17
|
|
|
Total
|
|
—
|
|
|
75
|
|
|
—
|
|
|
75
|
|
|
46
|
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign exchange contracts
|
|
—
|
|
|
23
|
|
|
—
|
|
|
23
|
|
|
34
|
|
|
Other investments
(5)
|
|
$
|
1,247
|
|
|
—
|
|
|
—
|
|
|
1,247
|
|
|
1,563
|
|
(1)
|
2011 assets and liabilities are all classified as Level 2 with the exception of Other investments of $
1,563 million
, which are classified as Level 1.
|
(2)
|
Includes $
96 million
and $
15 million
of non-current assets for the fiscal years ending
December 30, 2012
and
January 1, 2012
, respectively.
|
(3)
|
Includes $
4 million
and $
594 million
of non-current liabilities for the fiscal years ending
December 30, 2012
and
January 1, 2012
, respectively. Cross currency interest rate swaps related to outstanding EUR and GBP notes, matured in November 2012. The swaps were settled at fair market value and replaced with new swaps.
|
(4)
|
Currency option related to the acquisition of Synthes, Inc., which expired in January 2012.
|
(5)
|
Classified as non-current other assets.
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
33
|
7.
|
Borrowings
|
(Dollars in Millions)
|
|
2012
|
|
Effective Rate %
|
|
2011
|
|
Effective Rate %
|
|
|||||
5.15% Debentures due 2012
|
|
$
|
—
|
|
|
—
|
%
|
|
599
|
|
|
5.18
|
|
|
0.70% Notes due 2013
|
|
500
|
|
|
0.75
|
|
|
500
|
|
|
0.75
|
|
||
3.80% Debentures due 2013
|
|
500
|
|
|
3.82
|
|
|
500
|
|
|
3.82
|
|
||
3 month LIBOR+0% FRN due 2013
|
|
500
|
|
|
0.31
|
|
|
500
|
|
|
0.46
|
|
||
3 month LIBOR+0.09% FRN due 2014
|
|
750
|
|
|
0.40
|
|
|
750
|
|
|
0.55
|
|
||
1.20% Notes due 2014
|
|
999
|
|
|
1.24
|
|
|
999
|
|
|
1.24
|
|
||
2.15% Notes due 2016
|
|
898
|
|
|
2.22
|
|
|
898
|
|
|
2.22
|
|
||
5.55% Debentures due 2017
|
|
1,000
|
|
|
5.55
|
|
|
1,000
|
|
|
5.55
|
|
||
5.15% Debentures due 2018
|
|
898
|
|
|
5.15
|
|
|
898
|
|
|
5.15
|
|
||
4.75% Notes due 2019
(1B Euro 1.3275)
(2)
/
(1B Euro 1.2892)
(3)
|
|
1,321
|
|
(2)
|
5.83
|
|
|
1,282
|
|
(3)
|
5.35
|
|
||
3% Zero Coupon Convertible Subordinated Debentures due 2020
|
|
205
|
|
|
3.00
|
|
|
199
|
|
|
3.00
|
|
||
2.95% Debentures due 2020
|
|
542
|
|
|
3.15
|
|
|
541
|
|
|
3.15
|
|
||
3.55% Notes due 2021
|
|
446
|
|
|
3.67
|
|
|
446
|
|
|
3.67
|
|
||
6.73% Debentures due 2023
|
|
250
|
|
|
6.73
|
|
|
250
|
|
|
6.73
|
|
||
5.50% Notes due 2024 (500MM GBP 1.6169)
(2)
/(500MM GBP 1.5421)
(3)
|
|
803
|
|
(2)
|
6.75
|
|
|
765
|
|
(3)
|
5.71
|
|
||
6.95% Notes due 2029
|
|
296
|
|
|
7.14
|
|
|
294
|
|
|
7.14
|
|
||
4.95% Debentures due 2033
|
|
500
|
|
|
4.95
|
|
|
500
|
|
|
4.95
|
|
||
5.95% Notes due 2037
|
|
995
|
|
|
5.99
|
|
|
995
|
|
|
5.99
|
|
||
5.85% Debentures due 2038
|
|
700
|
|
|
5.86
|
|
|
700
|
|
|
5.86
|
|
||
4.50% Debentures due 2040
|
|
539
|
|
|
4.63
|
|
|
539
|
|
|
4.63
|
|
||
4.85% Notes due 2041
|
|
298
|
|
|
4.89
|
|
|
298
|
|
|
4.89
|
|
||
Other
|
|
61
|
|
|
—
|
|
|
132
|
|
|
—
|
|
||
|
|
13,001
|
|
(4)
|
4.14
|
|
(1)
|
13,585
|
|
(4)
|
4.08
|
(1
|
)
|
|
Less current portion
|
|
1,512
|
|
|
|
|
|
616
|
|
|
|
|
||
|
|
$
|
11,489
|
|
|
|
|
|
12,969
|
|
|
|
|
(1)
|
Weighted average effective rate.
|
(2)
|
Translation rate at
December 30, 2012
.
|
(3)
|
Translation rate at
January 1, 2012
.
|
(4)
|
The excess of the fair value over the carrying value of debt was
$2.2 billion
in
2012
and
$2.0 billion
in
2011
.
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
34
|
(Dollars in Millions)
|
|
|
|
|
|
|
|
|
||
2013
|
|
2014
|
|
2015
|
|
2016
|
|
2017
|
|
After 2017
|
$1,512
|
|
1,789
|
|
—
|
|
898
|
|
1,000
|
|
7,802
|
8.
|
Income Taxes
|
(Dollars in Millions)
|
|
2012
|
|
2011
|
|
2010
|
||||
Currently payable:
|
|
|
|
|
|
|
||||
U.S. taxes
|
|
$
|
2,023
|
|
|
2,392
|
|
|
2,063
|
|
International taxes
|
|
1,277
|
|
|
1,133
|
|
|
1,194
|
|
|
Total currently payable
|
|
3,300
|
|
|
3,525
|
|
|
3,257
|
|
|
Deferred:
|
|
|
|
|
|
|
||||
U.S. taxes
|
|
(120
|
)
|
|
(690
|
)
|
|
(4
|
)
|
|
International taxes
|
|
81
|
|
|
(146
|
)
|
|
360
|
|
|
Total deferred
|
|
(39
|
)
|
|
(836
|
)
|
|
356
|
|
|
Provision for taxes on income
|
|
$
|
3,261
|
|
|
2,689
|
|
|
3,613
|
|
(Dollars in Millions)
|
|
2012
|
|
2011
|
|
2010
|
||||
U.S.
|
|
$
|
4,664
|
|
|
3,634
|
|
|
6,392
|
|
International
|
|
9,111
|
|
|
8,727
|
|
|
10,555
|
|
|
Earnings before taxes on income:
|
|
$
|
13,775
|
|
|
12,361
|
|
|
16,947
|
|
Tax rates:
|
|
|
|
|
|
|
||||
U.S. statutory rate
|
|
35.0
|
%
|
|
35.0
|
|
|
35.0
|
|
|
International operations excluding Ireland
|
|
(9.8
|
)
|
|
(14.0
|
)
|
|
(7.5
|
)
|
|
Ireland and Puerto Rico operations
|
|
(3.9
|
)
|
|
(1.8
|
)
|
|
(5.1
|
)
|
|
Research and orphan drug tax credits
|
|
—
|
|
|
(0.8
|
)
|
|
(0.6
|
)
|
|
U.S. state and local
|
|
1.3
|
|
|
2.1
|
|
|
1.0
|
|
|
U.S. manufacturing deduction
|
|
(0.9
|
)
|
|
(0.8
|
)
|
|
(0.5
|
)
|
|
U.S. tax on international income
|
|
1.1
|
|
|
(0.4
|
)
|
|
(0.6
|
)
|
|
All other
(1)
|
|
0.9
|
|
|
2.5
|
|
|
(0.4
|
)
|
|
Effective tax rate
|
|
23.7
|
%
|
|
21.8
|
|
|
21.3
|
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
35
|
|
|
2012 Deferred Tax
|
|
2011 Deferred Tax
|
|||||||||
(Dollars in Millions)
|
|
Asset
|
|
Liability
|
|
Asset
|
|
Liability
|
|||||
Employee related obligations
|
|
$
|
3,343
|
|
|
|
|
|
3,028
|
|
|
|
|
Stock based compensation
|
|
1,199
|
|
|
|
|
|
1,358
|
|
|
|
|
|
Depreciation
|
|
|
|
|
(933
|
)
|
|
|
|
|
(865
|
)
|
|
Non-deductible intangibles
|
|
|
|
|
(6,261
|
)
|
|
|
|
|
(2,997
|
)
|
|
International R&D capitalized for tax
|
|
1,599
|
|
|
|
|
|
1,509
|
|
|
|
|
|
Reserves & liabilities
|
|
1,908
|
|
|
|
|
|
1,527
|
|
|
|
|
|
Income reported for tax purposes
|
|
726
|
|
|
|
|
|
903
|
|
|
|
|
|
Net operating loss carryforward international
|
|
1,117
|
|
|
|
|
|
1,183
|
|
|
|
|
|
Miscellaneous international
|
|
1,291
|
|
|
(371
|
)
|
|
1,261
|
|
|
(422
|
)
|
|
Miscellaneous U.S.
|
|
915
|
|
|
|
|
|
817
|
|
|
|
|
|
Total deferred income taxes
|
|
$
|
12,098
|
|
|
(7,565
|
)
|
|
11,586
|
|
|
(4,284
|
)
|
(Dollars in Millions)
|
|
2012
|
|
2011
|
|
2010
|
||||
Beginning of year
|
|
$
|
2,699
|
|
|
2,307
|
|
|
2,403
|
|
Increases related to current year tax positions
|
|
538
|
|
|
402
|
|
|
465
|
|
|
Increases related to prior period tax positions
|
|
57
|
|
|
87
|
|
|
68
|
|
|
Decreases related to prior period tax positions
|
|
(41
|
)
|
|
(77
|
)
|
|
(431
|
)
|
|
Settlements
|
|
(120
|
)
|
|
(16
|
)
|
|
(186
|
)
|
|
Lapse of statute of limitations
|
|
(79
|
)
|
|
(4
|
)
|
|
(12
|
)
|
|
End of year
|
|
$
|
3,054
|
|
|
2,699
|
|
|
2,307
|
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
36
|
9.
|
Employee Related Obligations
|
(Dollars in Millions)
|
|
2012
|
|
2011
|
|||
Pension benefits
|
|
$
|
4,488
|
|
|
3,937
|
|
Postretirement benefits
|
|
2,789
|
|
|
2,843
|
|
|
Postemployment benefits
|
|
1,452
|
|
|
1,129
|
|
|
Deferred compensation
|
|
747
|
|
|
863
|
|
|
Total employee obligations
|
|
9,476
|
|
|
8,772
|
|
|
Less current benefits payable
|
|
394
|
|
|
419
|
|
|
Employee related obligations — non-current
|
|
$
|
9,082
|
|
|
8,353
|
|
10.
|
Pensions and Other Benefit Plans
|
|
|
Retirement Plans
|
|
Other Benefit Plans
|
|||||||||||||||
(Dollars in Millions)
|
|
2012
|
|
2011
|
|
2010
|
|
2012
|
|
2011
|
|
2010
|
|||||||
Service cost
|
|
$
|
722
|
|
|
638
|
|
|
550
|
|
|
175
|
|
|
149
|
|
|
134
|
|
Interest cost
|
|
878
|
|
|
853
|
|
|
791
|
|
|
165
|
|
|
188
|
|
|
202
|
|
|
Expected return on plan assets
|
|
(1,236
|
)
|
|
(1,108
|
)
|
|
(1,005
|
)
|
|
(4
|
)
|
|
(1
|
)
|
|
(1
|
)
|
|
Amortization of prior service cost (credit)
|
|
6
|
|
|
9
|
|
|
10
|
|
|
(3
|
)
|
|
(3
|
)
|
|
(4
|
)
|
|
Amortization of net transition obligation
|
|
1
|
|
|
1
|
|
|
1
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
Recognized actuarial losses
|
|
494
|
|
|
388
|
|
|
236
|
|
|
76
|
|
|
45
|
|
|
48
|
|
|
Curtailments and settlements
|
|
—
|
|
|
—
|
|
|
1
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
Net periodic benefit cost
|
|
$
|
865
|
|
|
781
|
|
|
584
|
|
|
409
|
|
|
378
|
|
|
379
|
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
37
|
|
|
Retirement Plans
|
|
Other Benefit Plans
|
||||||||||||||
|
|
2012
|
|
2011
|
|
2010
|
|
2012
|
|
2011
|
|
2010
|
||||||
Worldwide Benefit Plans
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Discount rate
|
|
4.25
|
%
|
|
5.13
|
%
|
|
5.71
|
%
|
|
4.55
|
%
|
|
5.25
|
%
|
|
6.00
|
%
|
Expected long-term rate of return on plan assets
|
|
8.45
|
%
|
|
8.62
|
%
|
|
8.68
|
%
|
|
|
|
|
|
|
|||
Rate of increase in compensation levels
|
|
4.08
|
%
|
|
4.19
|
%
|
|
4.19
|
%
|
|
4.28
|
%
|
|
4.28
|
%
|
|
4.29
|
%
|
Health Care Plans
|
|
2012
|
|
2011
|
||
Health care cost trend rate assumed for next year
|
|
6.50
|
%
|
|
7.50
|
%
|
Rate to which the cost trend rate is assumed to decline (ultimate trend)
|
|
4.50
|
%
|
|
5.00
|
%
|
Year the rate reaches the ultimate trend rate
|
|
2032
|
|
|
2018
|
|
|
|
One-Percentage-
|
|
One-Percentage-
|
||||
(Dollars in Millions)
|
|
Point Increase
|
|
Point Decrease
|
||||
Health Care Plans
|
|
|
|
|
|
|
||
Total interest and service cost
|
|
$
|
42
|
|
|
$
|
(33
|
)
|
Post-retirement benefit obligation
|
|
496
|
|
|
(394
|
)
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
38
|
|
|
Retirement Plans
|
|
Other Benefit Plans
|
||||||||||
(Dollars in Millions)
|
|
2012
|
|
2011
|
|
2012
|
|
2011
|
||||||
Change in Benefit Obligation
|
|
|
|
|
|
|
|
|
||||||
Projected benefit obligation — beginning of year
|
|
$
|
17,424
|
|
|
14,993
|
|
|
3,790
|
|
|
3,572
|
|
|
Service cost
|
|
722
|
|
|
638
|
|
|
175
|
|
|
149
|
|
||
Interest cost
|
|
878
|
|
|
853
|
|
|
165
|
|
|
188
|
|
||
Plan participant contributions
|
|
35
|
|
|
54
|
|
|
—
|
|
|
—
|
|
||
Amendments
|
|
12
|
|
|
(24
|
)
|
|
—
|
|
|
—
|
|
||
Actuarial losses
|
|
2,662
|
|
|
1,698
|
|
|
459
|
|
|
213
|
|
||
Divestitures & acquisitions
|
|
629
|
|
|
14
|
|
|
—
|
|
|
—
|
|
||
Curtailments & settlements & restructuring
|
|
(6
|
)
|
|
(6
|
)
|
|
—
|
|
|
—
|
|
||
Benefits paid from plan
|
|
(697
|
)
|
|
(659
|
)
|
|
(432
|
)
|
|
(320
|
)
|
||
Effect of exchange rates
|
|
170
|
|
|
(137
|
)
|
|
2
|
|
|
(12
|
)
|
||
Projected benefit obligation — end of year
|
|
$
|
21,829
|
|
|
17,424
|
|
|
4,159
|
|
|
3,790
|
|
|
Change in Plan Assets
|
|
|
|
|
|
|
|
|
||||||
Plan assets at fair value — beginning of year
|
|
$
|
13,736
|
|
|
13,433
|
|
|
8
|
|
|
14
|
|
|
Actual return (loss) on plan assets
|
|
1,926
|
|
|
(102
|
)
|
|
3
|
|
|
(1
|
)
|
||
Company contributions
|
|
1,838
|
|
|
1,135
|
|
|
543
|
|
|
315
|
|
||
Plan participant contributions
|
|
35
|
|
|
54
|
|
|
—
|
|
|
—
|
|
||
Settlements
|
|
(2
|
)
|
|
(2
|
)
|
|
—
|
|
|
—
|
|
||
Divestitures & acquisitions
|
|
593
|
|
|
(2
|
)
|
|
—
|
|
|
—
|
|
||
Benefits paid from plan assets
|
|
(697
|
)
|
|
(659
|
)
|
|
(432
|
)
|
|
(320
|
)
|
||
Effect of exchange rates
|
|
107
|
|
|
(121
|
)
|
|
—
|
|
|
—
|
|
||
Plan assets at fair value — end of year
|
|
$
|
17,536
|
|
|
13,736
|
|
|
122
|
|
|
8
|
|
|
Funded status — end of year
|
|
$
|
(4,293
|
)
|
|
(3,688
|
)
|
|
(4,037
|
)
|
|
(3,782
|
)
|
|
Amounts Recognized in the Company’s Balance Sheet consist of the following:
|
|
|
|
|
|
|
|
|
||||||
Non-current assets
|
|
$
|
194
|
|
|
249
|
|
|
$
|
—
|
|
|
—
|
|
Current liabilities
|
|
(65
|
)
|
|
(59
|
)
|
|
(307
|
)
|
|
(346
|
)
|
||
Non-current liabilities
|
|
(4,422
|
)
|
|
(3,878
|
)
|
|
(3,730
|
)
|
|
(3,436
|
)
|
||
Total recognized in the consolidated balance sheet — end of year
|
|
$
|
(4,293
|
)
|
|
(3,688
|
)
|
|
$
|
(4,037
|
)
|
|
(3,782
|
)
|
Amounts Recognized in Accumulated Other Comprehensive Income consist of the following:
|
|
|
|
|
|
|
|
|
||||||
Net actuarial loss
|
|
$
|
7,586
|
|
|
6,030
|
|
|
$
|
1,601
|
|
|
1,218
|
|
Prior service cost (credit)
|
|
9
|
|
|
6
|
|
|
(14
|
)
|
|
(18
|
)
|
||
Unrecognized net transition obligation
|
|
2
|
|
|
3
|
|
|
—
|
|
|
1
|
|
||
Total before tax effects
|
|
$
|
7,597
|
|
|
6,039
|
|
|
$
|
1,587
|
|
|
1,201
|
|
|
|
|
|
|
|
|
|
|
||||||
Accumulated Benefit Obligations — end of year
|
|
$
|
19,267
|
|
|
15,452
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
39
|
|
|
Retirement Plans
|
|
Other Benefit Plans
|
||||||||||
(Dollars in Millions)
|
|
2012
|
|
2011
|
|
2012
|
|
2011
|
||||||
Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Income
|
|
|
|
|
|
|
|
|
||||||
Net periodic benefit cost
|
|
$
|
865
|
|
|
781
|
|
|
$
|
409
|
|
|
378
|
|
Net actuarial loss
|
|
2,007
|
|
|
2,903
|
|
|
458
|
|
|
197
|
|
||
Amortization of net actuarial (loss) gain
|
|
(494
|
)
|
|
(388
|
)
|
|
(76
|
)
|
|
8
|
|
||
Prior service cost
|
|
12
|
|
|
(24
|
)
|
|
—
|
|
|
—
|
|
||
Amortization of prior service (cost) credit
|
|
(6
|
)
|
|
(9
|
)
|
|
3
|
|
|
3
|
|
||
Effect of exchange rates
|
|
79
|
|
|
(25
|
)
|
|
1
|
|
|
(3
|
)
|
||
Total recognized in other comprehensive income, before tax
|
|
$
|
1,598
|
|
|
2,457
|
|
|
$
|
386
|
|
|
205
|
|
Total recognized in net periodic benefit cost and other comprehensive income
|
|
$
|
2,463
|
|
|
3,238
|
|
|
$
|
795
|
|
|
583
|
|
|
U.S. Plans
|
International Plans
|
|||||||||||||||
|
Qualified Plans
|
Non-Qualified Plans
|
Funded Plans
|
Unfunded Plans
|
|||||||||||||
(Dollars in Millions)
|
2012
|
2011
|
2012
|
2011
|
2012
|
2011
|
2012
|
2011
|
|||||||||
Plan Assets
|
$
|
11,464
|
|
9,132
|
|
—
|
|
—
|
|
6,072
|
|
4,604
|
|
—
|
|
—
|
|
Projected Benefit Obligation
|
12,420
|
|
10,283
|
|
1,343
|
|
1,155
|
|
7,586
|
|
5,626
|
|
480
|
|
360
|
|
|
Accumulated Benefit Obligation
|
11,001
|
|
9,147
|
|
1,070
|
|
903
|
|
6,774
|
|
5,078
|
|
422
|
|
324
|
|
|
Over (Under) Funded Status
|
|
|
|
|
|
|
|
|
|||||||||
Projected Benefit Obligation
|
$
|
(956
|
)
|
(1,151
|
)
|
(1,343
|
)
|
(1,155
|
)
|
(1,514
|
)
|
(1,022
|
)
|
(480
|
)
|
(360
|
)
|
Accumulated Benefit Obligation
|
463
|
|
(15
|
)
|
(1,070
|
)
|
(903
|
)
|
(702
|
)
|
(474
|
)
|
(422
|
)
|
(324
|
)
|
(Dollars in Millions)
|
|
2013
|
|
2014
|
|
2015
|
|
2016
|
|
2017
|
|
2018-2022
|
|||||||
Projected future benefit payments
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Retirement plans
|
|
$
|
695
|
|
|
715
|
|
|
736
|
|
|
775
|
|
|
820
|
|
|
4,934
|
|
Other benefit plans — gross
|
|
327
|
|
|
221
|
|
|
220
|
|
|
220
|
|
|
220
|
|
|
1,121
|
|
|
Medicare rebates
|
|
(11
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
Other benefit plans — net
|
|
$
|
316
|
|
|
221
|
|
|
220
|
|
|
220
|
|
|
220
|
|
|
1,121
|
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
40
|
(Dollars in Millions)
|
|
2013
|
|
2014
|
|
2015
|
|
2016
|
|
2017
|
|
2018-2022
|
|||||||
Projected future contributions
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Unfunded U.S. retirement plans
|
|
$
|
43
|
|
|
46
|
|
|
49
|
|
|
52
|
|
|
56
|
|
|
354
|
|
Unfunded international retirement plans
|
|
$
|
25
|
|
|
20
|
|
|
22
|
|
|
24
|
|
|
24
|
|
|
148
|
|
|
|
Percent of
Plan Assets
|
|
Target
Allocation
|
|||||
|
|
2012
|
|
2011
|
|
2013
|
|||
Worldwide Retirement Plans
|
|
|
|
|
|
|
|||
Equity securities
|
|
75
|
%
|
|
70
|
%
|
|
71
|
%
|
Debt securities
|
|
25
|
|
|
30
|
|
|
29
|
|
Total plan assets
|
|
100
|
%
|
|
100
|
%
|
|
100
|
%
|
•
|
Short-term investments
— Cash and quoted short-term instruments are valued at the closing price or the amount held on deposit by the custodian bank. Other investments are through investment vehicles valued using the Net Asset Value (NAV) provided by the administrator of the fund. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. The NAV is a quoted price in a market that is not active and classified as Level 2.
|
•
|
Government and agency securities
— A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified within Level 1 of the valuation hierarchy. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows. When quoted market prices for a security are not available in an active market, they are classified as Level 2.
|
•
|
Debt instruments
— A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified as Level 1. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows and are classified as Level 2. Level 3 debt instruments are priced based on unobservable inputs.
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
41
|
•
|
Equity securities
— Common stocks are valued at the closing price reported on the major market on which the individual securities are traded. Substantially all common stock is classified within Level 1 of the valuation hierarchy.
|
•
|
Commingled funds
— The investments are public investment vehicles valued using the NAV provided by the fund administrator. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. Assets in the Level 2 category have a quoted market price in a market that is not active.
|
•
|
Insurance contracts
— The instruments are issued by insurance companies. The fair value is based on negotiated value and the underlying investments held in separate account portfolios as well as considering the credit worthiness of the issuer. The underlying investments are government, asset-backed and fixed income securities. In general, insurance contracts are classified as Level 3 as there are no quoted prices nor other observable inputs for pricing.
|
•
|
Other assets
— Other assets are represented primarily by limited partnerships and real estate investments, as well as commercial loans and commercial mortgages that are not classified as corporate debt. Other assets that are exchange listed and actively traded are classified as Level 1, while inactively traded assets are classified as Level 2. Most limited partnerships represent investments in private equity and similar funds that are valued by the general partners. These, as well as any other assets valued using unobservable inputs, are classified as Level 3.
|
|
|
Quoted Prices
in Active
Markets for
Identical Assets
|
|
Significant
Other
Observable
Inputs
|
|
Significant
Unobserv-
able
Inputs
|
|
|
|
|
|||||||||||||||
|
|
(Level 1)
|
|
(Level 2)
|
|
(Level 3)
|
|
Total Assets
|
|||||||||||||||||
(Dollars in Millions)
|
|
2012
|
|
2011
|
|
2012
|
|
2011
|
|
2012
|
|
2011
|
|
2012
|
|
2011
|
|||||||||
Short-term investment funds
|
|
$
|
155
|
|
|
161
|
|
|
627
|
|
|
632
|
|
|
—
|
|
|
—
|
|
|
782
|
|
|
793
|
|
Government and agency securities
|
|
53
|
|
|
59
|
|
|
1,706
|
|
|
1,528
|
|
|
—
|
|
|
—
|
|
|
1,759
|
|
|
1,587
|
|
|
Debt instruments
|
|
2
|
|
|
1
|
|
|
1,641
|
|
|
1,106
|
|
|
3
|
|
|
9
|
|
|
1,646
|
|
|
1,116
|
|
|
Equity securities
|
|
8,104
|
|
|
6,682
|
|
|
1
|
|
|
2
|
|
|
4
|
|
|
16
|
|
|
8,109
|
|
|
6,700
|
|
|
Commingled funds
|
|
11
|
|
|
8
|
|
|
4,985
|
|
|
3,375
|
|
|
50
|
|
|
33
|
|
|
5,046
|
|
|
3,416
|
|
|
Insurance contracts
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
24
|
|
|
25
|
|
|
24
|
|
|
25
|
|
|
Other assets
|
|
—
|
|
|
1
|
|
|
101
|
|
|
33
|
|
|
69
|
|
|
65
|
|
|
170
|
|
|
99
|
|
|
Trust investments at fair value
|
|
$
|
8,325
|
|
|
6,912
|
|
|
9,061
|
|
|
6,676
|
|
|
150
|
|
|
148
|
|
|
17,536
|
|
|
13,736
|
|
(Dollars in Millions)
|
|
Debt Instruments
|
|
Equity Securities
|
|
Commingled Funds
|
|
Insurance Contracts
|
|
Other Assets
|
|
Total Level 3
|
|||||||
Balance January 2, 2011
|
|
$
|
13
|
|
|
24
|
|
|
35
|
|
|
29
|
|
|
82
|
|
|
183
|
|
Realized gains (losses)
|
|
—
|
|
|
3
|
|
|
—
|
|
|
1
|
|
|
—
|
|
|
4
|
|
|
Unrealized gains (losses)
|
|
1
|
|
|
(2
|
)
|
|
(6
|
)
|
|
(2
|
)
|
|
(17
|
)
|
|
(26
|
)
|
|
Purchases, sales, issuances and settlements, net
|
|
(5
|
)
|
|
(9
|
)
|
|
4
|
|
|
(3
|
)
|
|
—
|
|
|
(13
|
)
|
|
Balance January 1, 2012
|
|
9
|
|
|
16
|
|
|
33
|
|
|
25
|
|
|
65
|
|
|
148
|
|
|
Realized gains (losses)
|
|
—
|
|
|
(1
|
)
|
|
—
|
|
|
—
|
|
|
(5
|
)
|
|
(6
|
)
|
|
Unrealized gains (losses)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
Purchases, sales, issuances and settlements, net
|
|
(6
|
)
|
|
(11
|
)
|
|
17
|
|
|
(1
|
)
|
|
9
|
|
|
8
|
|
|
Balance December 30, 2012
|
|
$
|
3
|
|
|
4
|
|
|
50
|
|
|
24
|
|
|
69
|
|
|
150
|
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
42
|
11.
|
Savings Plan
|
12.
|
Capital and Treasury Stock
|
|
|
Treasury Stock
|
|||||
(Amounts in Millions Except Treasury Stock Shares in Thousands)
|
|
Shares
|
|
Amount
|
|||
Balance at January 3, 2010
|
|
365,522
|
|
|
$
|
19,780
|
|
Employee compensation and stock option plans
|
|
(28,866
|
)
|
|
(1,794
|
)
|
|
Repurchase of common stock
|
|
45,090
|
|
|
2,797
|
|
|
Balance at January 2, 2011
|
|
381,746
|
|
|
20,783
|
|
|
Employee compensation and stock option plans
|
|
(26,007
|
)
|
|
(1,649
|
)
|
|
Repurchase of common stock
|
|
39,741
|
|
|
2,525
|
|
|
Balance at January 1, 2012
|
|
395,480
|
|
|
21,659
|
|
|
Employee compensation and stock option plans
|
|
(55,170
|
)
|
|
(3,250
|
)
|
|
Issuance of common stock associated with the acquisition of Synthes, Inc.
|
|
(203,740
|
)
|
|
(12,852
|
)
|
|
Repurchase of common stock
(1)
|
|
204,784
|
|
|
12,919
|
|
|
Balance at December 30, 2012
|
|
341,354
|
|
|
$
|
18,476
|
|
(1)
|
Includes r
epurchase of
common stock associated with the acquisition of Synthes, Inc.
|
13.
|
Accumulated Other Comprehensive Income
|
(Dollars in Millions)
|
|
Foreign
Currency Translation |
|
Gains/
(Losses) on Securities |
|
Employee Benefit Plans
|
|
Gains/
(Losses) on Derivatives & Hedges |
|
Total
Accumulated Other Comprehensive Income/(Loss) |
||||||
January 3, 2010
|
|
$
|
(508
|
)
|
|
(30
|
)
|
|
(2,665
|
)
|
|
145
|
|
|
(3,058
|
)
|
Net 2010 changes
|
|
(461
|
)
|
|
54
|
|
|
(21
|
)
|
|
(45
|
)
|
|
(473
|
)
|
|
January 2, 2011
|
|
(969
|
)
|
|
24
|
|
|
(2,686
|
)
|
|
100
|
|
|
(3,531
|
)
|
|
Net 2011 changes
|
|
(557
|
)
|
|
424
|
|
|
(1,700
|
)
|
|
(268
|
)
|
|
(2,101
|
)
|
|
January 1, 2012
|
|
(1,526
|
)
|
|
448
|
|
|
(4,386
|
)
|
|
(168
|
)
|
|
(5,632
|
)
|
|
Net 2012 changes
|
|
1,230
|
|
|
(253
|
)
|
|
(1,331
|
)
|
|
176
|
|
|
(178
|
)
|
|
December 30, 2012
|
|
$
|
(296
|
)
|
|
195
|
|
|
(5,717
|
)
|
|
8
|
|
|
(5,810
|
)
|
14.
|
International Currency Translation
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
43
|
15.
|
Earnings Per Share
|
(In Millions Except Per Share Amounts)
|
|
2012
|
|
2011
|
|
2010
|
||||
Basic net earnings per share attributable to Johnson & Johnson
|
|
$
|
3.94
|
|
|
3.54
|
|
|
4.85
|
|
Average shares outstanding — basic
|
|
2,753.3
|
|
|
2,736.0
|
|
|
2,751.4
|
|
|
Potential shares exercisable under stock option plans
|
|
164.6
|
|
|
158.3
|
|
|
156.1
|
|
|
Less: shares repurchased under treasury stock method
|
|
(128.2
|
)
|
|
(122.6
|
)
|
|
(122.3
|
)
|
|
Convertible debt shares
|
|
3.6
|
|
|
3.6
|
|
|
3.6
|
|
|
Accelerated share repurchase program
|
|
19.3
|
|
|
—
|
|
|
—
|
|
|
Adjusted average shares outstanding — diluted
|
|
2,812.6
|
|
|
2,775.3
|
|
|
2,788.8
|
|
|
Diluted net earnings per share attributable to Johnson & Johnson
|
|
$
|
3.86
|
|
|
3.49
|
|
|
4.78
|
|
16.
|
Rental Expense and Lease Commitments
|
2013
|
|
2014
|
|
2015
|
|
2016
|
|
2017
|
|
After 2017
|
|
Total
|
$251
|
|
192
|
|
149
|
|
115
|
|
90
|
|
128
|
|
925
|
17.
|
Common Stock, Stock Option Plans and Stock Compensation Agreements
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
44
|
|
2012
|
|
2011
|
|
2010
|
|||
Risk-free rate
|
1.06
|
%
|
|
2.41
|
%
|
|
2.78
|
%
|
Expected volatility
|
18.38
|
%
|
|
18.20
|
%
|
|
17.40
|
%
|
Expected life (in years)
|
6.0
|
|
|
6.0
|
|
|
6.0
|
|
Dividend yield
|
3.60
|
%
|
|
3.60
|
%
|
|
3.30
|
%
|
(Shares in Thousands)
|
|
Outstanding Shares
|
|
Weighted
Average Exercise Price
|
|
Aggregate
Intrinsic
Value
(Dollars in Millions)
|
|||||
Shares at January 3, 2010
|
|
212,719
|
|
|
$
|
58.66
|
|
|
$
|
1,310
|
|
Options granted
|
|
13,996
|
|
|
62.62
|
|
|
|
|||
Options exercised
|
|
(25,020
|
)
|
|
51.84
|
|
|
|
|||
Options canceled/forfeited
|
|
(8,005
|
)
|
|
62.36
|
|
|
|
|||
Shares at January 2, 2011
|
|
193,690
|
|
|
59.68
|
|
|
648
|
|
||
Options granted
|
|
9,530
|
|
|
62.21
|
|
|
|
|||
Options exercised
|
|
(20,160
|
)
|
|
56.65
|
|
|
|
|||
Options canceled/forfeited
|
|
(3,601
|
)
|
|
62.38
|
|
|
|
|||
Shares at January 1, 2012
|
|
179,459
|
|
|
60.10
|
|
|
1,004
|
|
||
Options granted
|
|
8,661
|
|
|
65.36
|
|
|
|
|||
Options exercised
|
|
(49,388
|
)
|
|
56.73
|
|
|
|
|||
Options canceled/forfeited
|
|
(4,381
|
)
|
|
62.97
|
|
|
|
|||
Shares at December 30, 2012
|
|
134,351
|
|
|
$
|
61.58
|
|
|
$
|
1,061
|
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
45
|
(Shares in Thousands)
|
|
Outstanding
|
|
Exercisable
|
||||||||
Exercise Price Range
|
|
Options
|
|
Average Life
(1)
|
|
Average Exercise Price
|
|
Options
|
|
Average Exercise Price
|
||
$49.66-$53.77
|
|
3,600
|
|
|
0.1
|
|
$52.19
|
|
3,599
|
|
|
$52.19
|
$53.93-$58.33
|
|
29,134
|
|
|
3.6
|
|
$56.13
|
|
28,076
|
|
|
$56.04
|
$58.34-$61.75
|
|
29,604
|
|
|
4.0
|
|
$60.01
|
|
29,556
|
|
|
$60.01
|
$61.86-65.37
|
|
28,817
|
|
|
7.8
|
|
$63.29
|
|
464
|
|
|
$63.88
|
$65.62-$68.37
|
|
43,196
|
|
|
2.9
|
|
$65.97
|
|
43,165
|
|
|
$65.97
|
|
|
134,351
|
|
|
4.3
|
|
$61.58
|
|
104,860
|
|
|
$61.15
|
(Shares in Thousands)
|
|
Outstanding Restricted Share Units
|
|
Outstanding Performance Share Units
|
||
Shares at January 3, 2010
|
|
26,324
|
|
|
|
|
Granted
|
|
12,003
|
|
|
|
|
Issued
|
|
(6,297
|
)
|
|
|
|
Canceled/forfeited
|
|
(2,296
|
)
|
|
|
|
Shares at January 2, 2011
|
|
29,734
|
|
|
|
|
Granted
|
|
11,478
|
|
|
|
|
Issued
|
|
(8,300
|
)
|
|
|
|
Canceled/forfeited
|
|
(1,886
|
)
|
|
|
|
Shares at January 1, 2012
|
|
31,026
|
|
|
—
|
|
Granted
|
|
12,197
|
|
|
327
|
|
Issued
|
|
(9,278
|
)
|
|
—
|
|
Canceled/forfeited
|
|
(2,111
|
)
|
|
(42
|
)
|
Shares at December 30, 2012
|
|
31,834
|
|
|
285
|
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
46
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
47
|
18.
|
Segments of Business and Geographic Areas
|
|
|
Sales to Customers
|
||||||||
(Dollars in Millions)
|
|
2012
|
|
2011
|
|
2010
|
||||
Consumer —
|
|
|
|
|
|
|
||||
United States
|
|
$
|
5,046
|
|
|
5,151
|
|
|
5,519
|
|
International
|
|
9,401
|
|
|
9,732
|
|
|
9,071
|
|
|
Total
|
|
14,447
|
|
|
14,883
|
|
|
14,590
|
|
|
Pharmaceutical —
|
|
|
|
|
|
|
||||
United States
|
|
12,421
|
|
|
12,386
|
|
|
12,519
|
|
|
International
|
|
12,930
|
|
|
11,982
|
|
|
9,877
|
|
|
Total
|
|
25,351
|
|
|
24,368
|
|
|
22,396
|
|
|
Medical Devices and Diagnostics —
|
|
|
|
|
|
|
||||
United States
|
|
12,363
|
|
|
11,371
|
|
|
11,412
|
|
|
International
|
|
15,063
|
|
|
14,408
|
|
|
13,189
|
|
|
Total
|
|
27,426
|
|
|
25,779
|
|
|
24,601
|
|
|
Worldwide total
|
|
$
|
67,224
|
|
|
65,030
|
|
|
61,587
|
|
|
|
Pre-Tax Profit
|
|
Identifiable Assets
|
||||||||||||||||
(Dollars in Millions)
|
|
2012
(3)
|
|
2011
(4)
|
|
2010
(5)
|
|
2012
|
|
2011
|
|
2010
|
||||||||
Consumer
|
|
$
|
1,693
|
|
|
2,096
|
|
|
2,342
|
|
|
$
|
24,131
|
|
|
24,210
|
|
|
23,753
|
|
Pharmaceutical
|
|
6,075
|
|
|
6,406
|
|
|
7,086
|
|
|
23,219
|
|
|
23,747
|
|
|
19,961
|
|
||
Medical Devices and Diagnostics
|
|
7,187
|
|
|
5,263
|
|
|
8,272
|
|
|
42,926
|
|
|
23,609
|
|
|
23,277
|
|
||
Total
|
|
14,955
|
|
|
13,765
|
|
|
17,700
|
|
|
90,276
|
|
|
71,566
|
|
|
66,991
|
|
||
Less: Expense not allocated to segments
(1)
|
|
1,180
|
|
|
1,404
|
|
|
753
|
|
|
|
|
|
|
|
|||||
General corporate
(2)
|
|
|
|
|
|
|
|
31,071
|
|
|
42,078
|
|
|
35,917
|
|
|||||
Worldwide total
|
|
$
|
13,775
|
|
|
12,361
|
|
|
16,947
|
|
|
$
|
121,347
|
|
|
113,644
|
|
|
102,908
|
|
|
|
Additions to Property,
Plant & Equipment
|
|
Depreciation and
Amortization
|
||||||||||||||||
(Dollars in Millions)
|
|
2012
|
|
2011
|
|
2010
|
|
2012
|
|
2011
|
|
2010
|
||||||||
Consumer
|
|
$
|
468
|
|
|
670
|
|
|
526
|
|
|
$
|
575
|
|
|
631
|
|
|
532
|
|
Pharmaceutical
|
|
737
|
|
|
729
|
|
|
508
|
|
|
1,010
|
|
|
958
|
|
|
912
|
|
||
Medical Devices and Diagnostics
|
|
1,230
|
|
|
1,095
|
|
|
1,113
|
|
|
1,857
|
|
|
1,331
|
|
|
1,270
|
|
||
Segments total
|
|
2,435
|
|
|
2,494
|
|
|
2,147
|
|
|
3,442
|
|
|
2,920
|
|
|
2,714
|
|
||
General corporate
|
|
499
|
|
|
399
|
|
|
237
|
|
|
224
|
|
|
238
|
|
|
225
|
|
||
Worldwide total
|
|
$
|
2,934
|
|
|
2,893
|
|
|
2,384
|
|
|
$
|
3,666
|
|
|
3,158
|
|
|
2,939
|
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
48
|
|
|
Sales to Customers
|
|
Long-Lived Assets
(6)
|
||||||||||||||||
(Dollars in Millions)
|
|
2012
|
|
2011
|
|
2010
|
|
2012
|
|
2011
|
|
2010
|
||||||||
United States
|
|
$
|
29,830
|
|
|
28,908
|
|
|
29,450
|
|
|
$
|
35,115
|
|
|
23,529
|
|
|
23,315
|
|
Europe
|
|
16,945
|
|
|
17,129
|
|
|
15,510
|
|
|
25,261
|
|
|
19,056
|
|
|
16,791
|
|
||
Western Hemisphere excluding U.S.
|
|
7,207
|
|
|
6,418
|
|
|
5,550
|
|
|
3,636
|
|
|
3,517
|
|
|
3,653
|
|
||
Asia-Pacific, Africa
|
|
13,242
|
|
|
12,575
|
|
|
11,077
|
|
|
2,362
|
|
|
2,163
|
|
|
2,089
|
|
||
Segments total
|
|
67,224
|
|
|
65,030
|
|
|
61,587
|
|
|
66,374
|
|
|
48,265
|
|
|
45,848
|
|
||
General corporate
|
|
|
|
|
|
|
|
899
|
|
|
750
|
|
|
715
|
|
|||||
Other non long-lived assets
|
|
|
|
|
|
|
|
54,074
|
|
|
64,629
|
|
|
56,345
|
|
|||||
Worldwide total
|
|
$
|
67,224
|
|
|
65,030
|
|
|
61,587
|
|
|
$
|
121,347
|
|
|
113,644
|
|
|
102,908
|
|
(1)
|
Amounts not allocated to segments include interest (income) expense, noncontrolling interests and general corporate (income) expense. Includes expense of
$0.2 billion
and
$0.5 billion
of currency related expense related to the acquisition of Synthes, Inc. in 2012 and 2011, respectively.
|
(2)
|
General corporate includes cash and marketable securities.
|
(3)
|
Includes
$1,218 million
of net litigation expense, which includes product liability, comprised of
$658 million
and
$560 million
in the Pharmaceutical and Medical Devices and Diagnostics segments, respectively. Includes
$1,163 million
of in-process research and development expense, comprised of
$1,111 million
and
$52 million
in the Pharmaceutical and Medical Devices and Diagnostics segments, respectively. Includes
$795 million
of Synthes integration/transaction costs in the Medical Devices and Diagnostics segment. Includes
$909 million
of asset write-downs and other adjustments, comprised of
$499 million
,
$264 million
and
$146 million
in the Pharmaceutical, Consumer and Medical Devices and Diagnostics segments, respectively. The Medical Devices and Diagnostics segment also includes
$110 million
expense for the cost associated with the DePuy ASR
™
Hip program.
|
(4)
|
Includes
$3,310 million
of net litigation expense, which includes product liability, comprised of
$1,741 million
and
$1,569 million
in the Pharmaceutical and Medical Devices and Diagnostics segments, respectively. Includes
$656 million
of net restructuring expense, comprised of
$676 million
expense in the Medical Devices and Diagnostics segment and a gain of
$20 million
in the Pharmaceutical segment. The Medical Devices and Diagnostics segment also includes
$521 million
expense for the cost associated with the DePuy ASR
™
Hip program.
|
(5)
|
Includes
$397 million
of net litigation gain, which includes product liability expense, comprised of
$447 million
expense in the Pharmaceutical segment and a gain of
$844 million
in the Medical Devices and Diagnostics segment. The Medical Devices and Diagnostics segment also includes
$280 million
expense for the cost associated with the DePuy ASR
™
Hip program.
|
(6)
|
Long-lived assets include property, plant and equipment, net for
2012
,
2011
and
2010
of
$16,097
,
$14,739
and
$14,553
, respectively, and intangible assets and goodwill, net for
2012
,
2011
and
2010
of
$51,176
,
$34,276
and
$32,010
, respectively.
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
49
|
19.
|
Selected Quarterly Financial Data (unaudited)
|
|
|
2012
|
|
2011
|
|||||||||||||||||||||
(Dollars in Millions Except Per Share Data)
|
|
First Quarter
(1)
|
|
Second Quarter
(2)
|
|
Third Quarter
(3)
|
|
Fourth Quarter
(4)
|
|
First Quarter
(5)
|
|
Second Quarter
(6)
|
|
Third Quarter
(7)
|
|
Fourth Quarter
(8)
|
|||||||||
Segment sales to customers
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consumer
|
|
$
|
3,595
|
|
|
3,619
|
|
|
3,581
|
|
|
3,652
|
|
|
3,682
|
|
|
3,793
|
|
|
3,740
|
|
|
3,668
|
|
Pharmaceutical
|
|
6,133
|
|
|
6,291
|
|
|
6,402
|
|
|
6,525
|
|
|
6,059
|
|
|
6,233
|
|
|
5,982
|
|
|
6,094
|
|
|
Med Devices & Diagnostics
|
|
6,411
|
|
|
6,565
|
|
|
7,069
|
|
|
7,381
|
|
|
6,432
|
|
|
6,571
|
|
|
6,283
|
|
|
6,493
|
|
|
Total sales
|
|
16,139
|
|
|
16,475
|
|
|
17,052
|
|
|
17,558
|
|
|
16,173
|
|
|
16,597
|
|
|
16,005
|
|
|
16,255
|
|
|
Gross profit
|
|
11,224
|
|
|
11,332
|
|
|
11,455
|
|
|
11,555
|
|
|
11,395
|
|
|
11,425
|
|
|
10,933
|
|
|
10,917
|
|
|
Earnings before provision for taxes on income
|
|
5,045
|
|
|
2,035
|
|
|
3,595
|
|
|
3,100
|
|
|
4,510
|
|
|
3,422
|
|
|
4,111
|
|
|
318
|
|
|
Net earnings attributable to Johnson & Johnson
|
|
3,910
|
|
|
1,408
|
|
|
2,968
|
|
|
2,567
|
|
|
3,476
|
|
|
2,776
|
|
|
3,202
|
|
|
218
|
|
|
Basic net earnings per share attributable to Johnson & Johnson
|
|
$
|
1.43
|
|
|
0.51
|
|
|
1.08
|
|
|
0.93
|
|
|
1.27
|
|
|
1.01
|
|
|
1.17
|
|
|
0.08
|
|
Diluted net earnings per share attributable to Johnson & Johnson
|
|
$
|
1.41
|
|
|
0.50
|
|
|
1.05
|
|
|
0.91
|
|
|
1.25
|
|
|
1.00
|
|
|
1.15
|
|
|
0.08
|
|
(1)
|
The first quarter of 2012 includes an after-tax gain of
$106 million
from currency and costs associated with the acquisition of Synthes, Inc.
|
(2)
|
The second quarter of 2012 includes after-tax charges of
$717 million
for asset write-downs,
$611 million
from net litigation,
$564 million
associated with the acquisition of Synthes, Inc. and
$344 million
from impairment of in-process research and development.
|
(3)
|
The third quarter of 2012 includes after-tax charges of
$135 million
associated with the acquisition of Synthes, Inc.,
$340 million
from impairment of in-process research and development,
$70 million
associated with litigation, including product liability, and
$24 million
associated with the DePuy ASR
™
Hip program.
|
(4)
|
The fourth quarter of 2012 includes after-tax charges of
$371 million
from net litigation, including product liability,
$306 million
associated with the acquisition of Synthes, Inc.,
$73 million
associated with the DePuy ASR
™
Hip program and
$59 million
from impairment of in-process research and development.
|
(5)
|
The first quarter of 2011 includes an after-tax charge of
$271 million
from net litigation, including product liability, and the DePuy ASR
™
Hip program.
|
(6)
|
The second quarter of 2011 includes after-tax charges of
$549 million
for restructuring,
$325 million
from litigation, including product liability, and the DePuy ASR
™
Hip program, partially offset by a
$102 million
after-tax gain associated with an adjustment to the value of the currency option related to the acquisition of Synthes, Inc.
|
(7)
|
The third quarter of 2011 includes a
$241 million
after-tax charge associated with an adjustment to the value of the currency option and deal costs related to the acquisition of Synthes, Inc.
|
(8)
|
The fourth quarter of 2011 includes after-tax charges of
$2,239 million
from net litigation, including product liability,
$336 million
for the cost associated with the DePuy ASR
™
Hip program and
$338 million
associated with an adjustment to the value of the currency option and deal costs related to the acquisition of Synthes, Inc.
|
20.
|
Business Combinations and Divestitures
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
50
|
(Dollars in Millions)
|
|
|
||
Cash (multiply 55.65CHF by shares of Synthes common stock outstanding by the exchange rate)
(A)
|
|
$
|
6,902
|
|
Common Stock (multiply 1.717 by shares of Synthes common stock outstanding by J&J stock price)
(B)
|
|
$
|
13,335
|
|
Total fair value of consideration transferred
|
|
$
|
20,237
|
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
51
|
(Dollars in Millions)
|
June 14, 2012
|
December 30, 2012
|
|||
Cash & Cash equivalents
|
$
|
2,749
|
|
2,749
|
|
Inventory
|
889
|
|
1,194
|
|
|
Accounts Receivable, net
|
738
|
|
738
|
|
|
Other current assets
|
249
|
|
238
|
|
|
Property, plant and equipment
|
1,253
|
|
1,253
|
|
|
Goodwill
|
5,371
|
|
6,011
|
|
|
Intangible assets
|
12,929
|
|
12,861
|
|
|
Other non-current assets
|
46
|
|
46
|
|
|
Total Assets Acquired
|
24,224
|
|
25,090
|
|
|
|
|
|
|||
Current liabilities
|
825
|
|
1,053
|
|
|
Deferred Taxes
|
2,731
|
|
3,471
|
|
|
Other non-current liabilities
|
431
|
|
329
|
|
|
Total Liabilities Assumed
|
3,987
|
|
4,853
|
|
|
|
|
|
|||
Net Assets Acquired
|
$
|
20,237
|
|
20,237
|
|
(Dollars in Millions)
|
|
June 14, 2012
|
December 30, 2012
|
|||
Intangible assets with definite lives:
|
|
|
|
|||
Customer relationships
|
|
$
|
9,950
|
|
9,870
|
|
Patents and technology
|
|
1,495
|
|
1,508
|
|
|
Total amortizable intangibles
|
|
11,445
|
|
11,378
|
|
|
|
|
|
|
|||
Trademark and Trade name
|
|
1,420
|
|
1,420
|
|
|
In-process research and development
|
|
64
|
|
63
|
|
|
Total intangible assets
|
|
$
|
12,929
|
|
12,861
|
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
52
|
|
Unaudited Pro forma consolidated results
|
||||
(Dollars in Millions Except Per Share Amounts)
|
2012
|
2011
|
|||
|
|
|
|||
Net Sales
|
$
|
68,894
|
|
68,741
|
|
Net Earnings attributable to Johnson & Johnson
|
$
|
11,564
|
|
9,427
|
|
Diluted Net Earnings per share attributable to Johnson & Johnson
|
$
|
4.11
|
|
3.40
|
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
53
|
21.
|
Legal Proceedings
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
54
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
55
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
56
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
57
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
58
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
59
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
60
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
61
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
62
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
63
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
64
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
65
|
22.
|
Restructuring
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
66
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
67
|
|
|
|
Alex Gorsky
|
|
Dominic J. Caruso
|
Chairman, Board of Directors
|
|
Vice President, Finance
|
Chief Executive Officer
|
|
Chief Financial Officer
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
68
|
(Dollars in Millions Except Per Share Amounts)
|
2012
|
|
2011
|
|
2010
|
|
2009
|
|
2008
|
|
2007
|
|
2006
|
|
2005
|
|
2004
|
|
2003
|
|
2002
|
||||||||||||
Sales to customers — U.S.
|
$
|
29,830
|
|
|
28,908
|
|
|
29,450
|
|
|
30,889
|
|
|
32,309
|
|
|
32,444
|
|
|
29,775
|
|
|
28,377
|
|
|
27,770
|
|
|
25,274
|
|
|
22,455
|
|
Sales to customers — International
|
37,394
|
|
|
36,122
|
|
|
32,137
|
|
|
31,008
|
|
|
31,438
|
|
|
28,651
|
|
|
23,549
|
|
|
22,137
|
|
|
19,578
|
|
|
16,588
|
|
|
13,843
|
|
|
Total sales
|
67,224
|
|
|
65,030
|
|
|
61,587
|
|
|
61,897
|
|
|
63,747
|
|
|
61,095
|
|
|
53,324
|
|
|
50,514
|
|
|
47,348
|
|
|
41,862
|
|
|
36,298
|
|
|
Cost of products sold
|
21,658
|
|
|
20,360
|
|
|
18,792
|
|
|
18,447
|
|
|
18,511
|
|
|
17,751
|
|
|
15,057
|
|
|
14,010
|
|
|
13,474
|
|
|
12,231
|
|
|
10,498
|
|
|
Selling, marketing and administrative expenses
|
20,869
|
|
|
20,969
|
|
|
19,424
|
|
|
19,801
|
|
|
21,490
|
|
|
20,451
|
|
|
17,433
|
|
|
17,211
|
|
|
16,174
|
|
|
14,463
|
|
|
12,520
|
|
|
Research and development expense
|
7,665
|
|
|
7,548
|
|
|
6,844
|
|
|
6,986
|
|
|
7,577
|
|
|
7,680
|
|
|
7,125
|
|
|
6,462
|
|
|
5,344
|
|
|
4,834
|
|
|
4,094
|
|
|
In-process research and development
|
1,163
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
181
|
|
|
807
|
|
|
559
|
|
|
362
|
|
|
18
|
|
|
918
|
|
|
189
|
|
|
Interest income
|
(64
|
)
|
|
(91
|
)
|
|
(107
|
)
|
|
(90
|
)
|
|
(361
|
)
|
|
(452
|
)
|
|
(829
|
)
|
|
(487
|
)
|
|
(195
|
)
|
|
(177
|
)
|
|
(256
|
)
|
|
Interest expense, net of portion capitalized
|
532
|
|
|
571
|
|
|
455
|
|
|
451
|
|
|
435
|
|
|
296
|
|
|
63
|
|
|
54
|
|
|
187
|
|
|
207
|
|
|
160
|
|
|
Other (income) expense, net
|
1,626
|
|
|
2,743
|
|
|
(768
|
)
|
|
(526
|
)
|
|
(1,015
|
)
|
|
534
|
|
|
(671
|
)
|
|
(214
|
)
|
|
15
|
|
|
(385
|
)
|
|
294
|
|
|
Restructuring
|
—
|
|
|
569
|
|
|
—
|
|
|
1,073
|
|
|
—
|
|
|
745
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
|
53,449
|
|
|
52,669
|
|
|
44,640
|
|
|
46,142
|
|
|
46,818
|
|
|
47,812
|
|
|
38,737
|
|
|
37,398
|
|
|
35,017
|
|
|
32,091
|
|
|
27,499
|
|
|
Earnings before provision for taxes on income
|
$
|
13,775
|
|
|
12,361
|
|
|
16,947
|
|
|
15,755
|
|
|
16,929
|
|
|
13,283
|
|
|
14,587
|
|
|
13,116
|
|
|
12,331
|
|
|
9,771
|
|
|
8,799
|
|
Provision for taxes on income
|
3,261
|
|
|
2,689
|
|
|
3,613
|
|
|
3,489
|
|
|
3,980
|
|
|
2,707
|
|
|
3,534
|
|
|
3,056
|
|
|
4,151
|
|
|
2,923
|
|
|
2,522
|
|
|
Net earnings
|
10,514
|
|
|
9,672
|
|
|
13,334
|
|
|
12,266
|
|
|
12,949
|
|
|
10,576
|
|
|
11,053
|
|
|
10,060
|
|
|
8,180
|
|
|
6,848
|
|
|
6,277
|
|
|
Add: Net loss attributable to noncontrolling interest
|
339
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
Net earnings attributable to Johnson & Johnson
|
10,853
|
|
|
9,672
|
|
|
13,334
|
|
|
12,266
|
|
|
12,949
|
|
|
10,576
|
|
|
11,053
|
|
|
10,060
|
|
|
8,180
|
|
|
6,848
|
|
|
6,277
|
|
|
Percent of sales to customers
|
16.1
|
%
|
|
14.9
|
|
|
21.7
|
|
|
19.8
|
|
|
20.3
|
|
|
17.3
|
|
|
20.7
|
|
|
19.9
|
|
|
17.3
|
|
|
16.4
|
|
|
17.3
|
|
|
Diluted net earnings per share of common stock
(1)
|
$
|
3.86
|
|
|
3.49
|
|
|
4.78
|
|
|
4.40
|
|
|
4.57
|
|
|
3.63
|
|
|
3.73
|
|
|
3.35
|
|
|
2.74
|
|
|
2.29
|
|
|
2.06
|
|
Percent return on average shareholders’ equity
|
17.8
|
%
|
|
17.0
|
|
|
24.9
|
|
|
26.4
|
|
|
30.2
|
|
|
25.6
|
|
|
28.3
|
|
|
28.2
|
|
|
27.3
|
|
|
27.1
|
|
|
26.4
|
|
|
Percent increase (decrease) over previous year:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Sales to customers
|
3.4
|
%
|
|
5.6
|
|
|
(0.5
|
)
|
|
(2.9
|
)
|
|
4.3
|
|
|
14.6
|
|
|
5.6
|
|
|
6.7
|
|
|
13.1
|
|
|
15.3
|
|
|
12.3
|
|
|
Diluted net earnings per share
|
10.6
|
%
|
|
(27.0
|
)
|
|
8.6
|
|
|
(3.7
|
)
|
|
25.9
|
|
|
(2.7
|
)
|
|
11.3
|
|
|
22.3
|
|
|
19.7
|
|
|
11.2
|
|
|
17.7
|
|
|
Supplementary balance sheet data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Property, plant and equipment, net
|
16,097
|
|
|
14,739
|
|
|
14,553
|
|
|
14,759
|
|
|
14,365
|
|
|
14,185
|
|
|
13,044
|
|
|
10,830
|
|
|
10,436
|
|
|
9,846
|
|
|
8,710
|
|
|
Additions to property, plant and equipment
|
2,934
|
|
|
2,893
|
|
|
2,384
|
|
|
2,365
|
|
|
3,066
|
|
|
2,942
|
|
|
2,666
|
|
|
2,632
|
|
|
2,175
|
|
|
2,262
|
|
|
2,099
|
|
|
Total assets
|
121,347
|
|
|
113,644
|
|
|
102,908
|
|
|
94,682
|
|
|
84,912
|
|
|
80,954
|
|
|
70,556
|
|
|
58,864
|
|
|
54,039
|
|
|
48,858
|
|
|
40,984
|
|
|
Long-term debt
|
11,489
|
|
|
12,969
|
|
|
9,156
|
|
|
8,223
|
|
|
8,120
|
|
|
7,074
|
|
|
2,014
|
|
|
2,017
|
|
|
2,565
|
|
|
2,955
|
|
|
2,022
|
|
|
Operating cash flow
|
15,396
|
|
|
14,298
|
|
|
16,385
|
|
|
16,571
|
|
|
14,972
|
|
|
15,022
|
|
|
14,248
|
|
|
11,799
|
|
|
11,089
|
|
|
10,571
|
|
|
8,135
|
|
|
Common stock information
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
Dividends paid per share
|
$
|
2.400
|
|
|
2.250
|
|
|
2.110
|
|
|
1.930
|
|
|
1.795
|
|
|
1.620
|
|
|
1.455
|
|
|
1.275
|
|
|
1.095
|
|
|
0.925
|
|
|
0.795
|
|
Shareholders’ equity per share
|
23.33
|
|
|
20.95
|
|
|
20.66
|
|
|
18.37
|
|
|
15.35
|
|
|
15.25
|
|
|
13.59
|
|
|
13.01
|
|
|
10.95
|
|
|
9.25
|
|
|
7.79
|
|
|
Market price per share (year-end close)
|
$
|
69.48
|
|
|
65.58
|
|
|
61.85
|
|
|
64.41
|
|
|
58.56
|
|
|
67.38
|
|
|
66.02
|
|
|
60.10
|
|
|
63.42
|
|
|
50.62
|
|
|
53.11
|
|
Average shares outstanding (millions)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
— basic
|
2,753.3
|
|
|
2,736.0
|
|
|
2,751.4
|
|
|
2,759.5
|
|
|
2,802.5
|
|
|
2,882.9
|
|
|
2,936.4
|
|
|
2,973.9
|
|
|
2,968.4
|
|
|
2,968.1
|
|
|
2,998.3
|
|
|
— diluted
|
2,812.6
|
|
|
2,775.3
|
|
|
2,788.8
|
|
|
2,789.1
|
|
|
2,835.6
|
|
|
2,910.7
|
|
|
2,961.0
|
|
|
3,002.8
|
|
|
2,992.7
|
|
|
2,995.1
|
|
|
3,049.1
|
|
|
Employees (thousands)
|
127.6
|
|
|
117.9
|
|
|
114.0
|
|
|
115.5
|
|
|
118.7
|
|
|
119.2
|
|
|
122.2
|
|
|
115.6
|
|
|
109.9
|
|
|
110.6
|
|
|
108.3
|
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
|
69
|
|
2007
|
2008
|
2009
|
2010
|
2011
|
2012
|
||||||||||||
Johnson & Johnson
|
$
|
100.00
|
|
$
|
92.23
|
|
$
|
102.63
|
|
$
|
102.03
|
|
$
|
112.13
|
|
$
|
124.24
|
|
S&P 500 Index
|
$
|
100.00
|
|
$
|
63.00
|
|
$
|
79.67
|
|
$
|
91.68
|
|
$
|
93.61
|
|
$
|
108.59
|
|
S&P 500 Pharmaceutical Index
|
$
|
100.00
|
|
$
|
81.80
|
|
$
|
97.03
|
|
$
|
97.78
|
|
$
|
115.14
|
|
$
|
131.75
|
|
S&P 500 Healthcare Equipment Index
|
$
|
100.00
|
|
$
|
72.36
|
|
$
|
93.18
|
|
$
|
90.66
|
|
$
|
89.93
|
|
$
|
105.46
|
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
|
70
|
|
2002
|
2003
|
2004
|
2005
|
2006
|
2007
|
2008
|
2009
|
2010
|
2011
|
2012
|
||||||||||||||||||||||
Johnson & Johnson
|
$
|
100.00
|
|
$
|
97.89
|
|
$
|
122.52
|
|
$
|
118.41
|
|
$
|
133.14
|
|
$
|
137.95
|
|
$
|
127.23
|
|
$
|
141.58
|
|
$
|
140.75
|
|
$
|
154.68
|
|
$
|
171.38
|
|
S&P 500 Index
|
$
|
100.00
|
|
$
|
128.68
|
|
$
|
142.68
|
|
$
|
149.69
|
|
$
|
173.33
|
|
$
|
182.85
|
|
$
|
115.20
|
|
$
|
145.69
|
|
$
|
167.63
|
|
$
|
171.17
|
|
$
|
198.57
|
|
S&P 500 Pharmaceutical Index
|
$
|
100.00
|
|
$
|
108.78
|
|
$
|
100.70
|
|
$
|
97.31
|
|
$
|
112.74
|
|
$
|
117.98
|
|
$
|
96.51
|
|
$
|
114.48
|
|
$
|
115.36
|
|
$
|
135.85
|
|
$
|
155.45
|
|
S&P 500 Healthcare Equipment Index
|
$
|
100.00
|
|
$
|
132.04
|
|
$
|
148.70
|
|
$
|
148.78
|
|
$
|
154.92
|
|
$
|
162.86
|
|
$
|
117.84
|
|
$
|
151.76
|
|
$
|
147.65
|
|
$
|
146.47
|
|
$
|
171.76
|
|
JOHNSON & JOHNSON 2012 ANNUAL REPORT
|
|
71
|
Name of Subsidiary
|
Jurisdiction of Organization
|
U.S. Subsidiaries:
|
|
Acclarent, Inc.
|
Delaware
|
ALZA Corporation
|
Delaware
|
Animas Corporation
|
Delaware
|
Biosense Webster, Inc.
|
California
|
CNA Development LLC
|
Delaware
|
Codman & Shurtleff, Inc.
|
New Jersey
|
Cordis Corporation
|
Florida
|
Cordis International Corporation
|
Delaware
|
Cordis LLC
|
Delaware
|
DePuy Mitek Holding Corporation
|
Delaware
|
DePuy Mitek, LLC
|
Massachusetts
|
DePuy Orthopaedics, Inc.
|
Indiana
|
DePuy Products, Inc.
|
Indiana
|
DePuy Spine, LLC
|
Ohio
|
DePuy Synthes Sales, Inc.
|
Massachusetts
|
DePuy Synthes, Inc.
|
Delaware
|
Diabetes Diagnostics, Inc.
|
Delaware
|
Ethicon Endo-Surgery, Inc.
|
New Jersey
|
Ethicon Endo-Surgery, LLC
|
Delaware
|
Ethicon LLC
|
Delaware
|
Ethicon US, LLC
|
Texas
|
Ethicon, Inc.
|
New Jersey
|
ISO Holding Corp.
|
Delaware
|
J&J Holdings (Nevada), Inc.
|
Nevada
|
Janssen Alzheimer Immunotherapy Research & Development, LLC
|
Delaware
|
Janssen Biotech, Inc.
|
Pennsylvania
|
Janssen Global Services, LLC
|
New Jersey
|
Janssen Oncology, Inc.
|
Delaware
|
Janssen Ortho LLC
|
Delaware
|
Janssen Pharmaceuticals, Inc.
|
Pennsylvania
|
Janssen Products, LP
|
New Jersey
|
Janssen Research & Development, LLC
|
New Jersey
|
Janssen Scientific Affairs, LLC
|
New Jersey
|
Janssen Services, LLC
|
New Jersey
|
Janssen Supply Group, LLC
|
Pennsylvania
|
Janssen-Cilag Manufacturing, LLC
|
Delaware
|
JJHC, LLC
|
Delaware
|
JNJ International Investment LLC
|
Delaware
|
Johnson & Johnson (Middle East) Inc.
|
New Jersey
|
Johnson & Johnson Consumer Companies, Inc.
|
New Jersey
|
Johnson & Johnson Development Corporation
|
New Jersey
|
Johnson & Johnson Finance Corporation
|
New Jersey
|
Johnson & Johnson Health Care Systems Inc.
|
New Jersey
|
Johnson & Johnson International
|
New Jersey
|
Johnson & Johnson Japan Inc.
|
New Jersey
|
Johnson & Johnson Sales and Logistics Company, LLC
|
New Jersey
|
Johnson & Johnson Services, Inc.
|
New Jersey
|
Johnson & Johnson Urban Renewal Associates
|
New Jersey
|
Name of Subsidiary
|
Jurisdiction of Organization
|
Johnson & Johnson Vision Care, Inc.
|
Florida
|
JOM Pharmaceutical Services, Inc.
|
Delaware
|
LifeScan LLC
|
Delaware
|
LifeScan Products, LLC
|
Delaware
|
LifeScan, Inc.
|
California
|
McNeil Consumer Pharmaceuticals Co.
|
New Jersey
|
McNeil Healthcare LLC
|
Delaware
|
McNeil LA LLC
|
Delaware
|
McNEIL MMP, LLC
|
New Jersey
|
McNeil Nutritionals, LLC
|
Delaware
|
McNEIL-PPC, Inc.
|
New Jersey
|
Mentor Texas L.P.
|
Delaware
|
Mentor Worldwide LLC
|
Delaware
|
Micro Typing Systems, Inc.
|
Florida
|
Micrus Endovascular LLC
|
Delaware
|
Middlesex Assurance Company Limited
|
Vermont
|
Neutrogena Corporation
|
Delaware
|
Nitinol Development Corporation
|
California
|
Noramco, Inc.
|
Georgia
|
OMJ Pharmaceuticals, Inc.
|
Delaware
|
Omrix Biopharmaceuticals, Inc.
|
Delaware
|
Ortho Biologics LLC
|
Delaware
|
Ortho-Clinical Diagnostics, Inc.
|
New York
|
Refresh Holdings, Inc.
|
Delaware
|
Rutan Realty LLC
|
New Jersey
|
Scios Inc.
|
Delaware
|
SterilMed, Inc.
|
Minnesota
|
Synthes USA Products, LLC
|
Delaware
|
Synthes USA, LLC
|
Delaware
|
Synthes, Inc.
|
Delaware
|
The Anspach Effort, LLC
|
Florida
|
Wellness & Prevention, Inc.
|
Michigan
|
International Subsidiaries:
|
|
Almaco Holding AG
|
Switzerland
|
Apsis
|
France
|
Apsis Germany GmbH
|
Germany
|
Beijing Dabao Cosmetics Co., Ltd.
|
China
|
Berna Biotech Korea Corporation
|
Korea, Republic of
|
Berna Rhein B.V.
|
Netherlands
|
Biosense Webster (Israel) Ltd.
|
Israel
|
Cilag Advanced Technologies GmbH
|
Switzerland
|
Cilag AG
|
Switzerland
|
Cilag GmbH International
|
Switzerland
|
Cilag Holding AG
|
Switzerland
|
Cilag Pharmaceuticals GmbH
|
Switzerland
|
Cordis
|
France
|
|
|
Name of Subsidiary
|
Jurisdiction of Organization
|
Cordis de Mexico, S.A. de C.V.
|
Mexico
|
Cordis Europa NV
|
Netherlands
|
Cordis Medizinische Apparate GmbH
|
Germany
|
Corimmun GmbH
|
Germany
|
Crucell Holland B.V.
|
Netherlands
|
Crucell N.V.
|
Netherlands
|
Crucell Sweden AB
|
Sweden
|
Crucell Switzerland AG
|
Switzerland
|
DePuy (Ireland)
|
Ireland
|
DePuy France
|
France
|
DePuy International (Holdings) Limited
|
United Kingdom
|
DePuy International Limited
|
United Kingdom
|
DePuy Medical Private Limited
|
India
|
DePuy Mitek Sarl
|
Switzerland
|
DePuy Motion Sarl
|
Switzerland
|
DePuy Orthopadie GmbH
|
Germany
|
DePuy UK Holdings Limited
|
United Kingdom
|
EES Holdings de Mexico, S. de R.L. de C.V.
|
Mexico
|
Ethicon
|
France
|
Ethicon Ireland
|
Ireland
|
Ethicon PR Holdings
|
Ireland
|
Ethicon Women's Health & Urology Sarl
|
Switzerland
|
Ethnor Farmaceutica, S.A.
|
Venezuela
|
FMS Future Medical System SA
|
Switzerland
|
GMED Healthcare BVBA
|
Belgium
|
High Wycombe Property Management Limited
|
United Kingdom
|
J.C. General Services CVBA
|
Belgium
|
Janssen Alzheimer Immunotherapy
|
Ireland
|
Janssen Alzheimer Immunotherapy (Holding) Limited
|
Ireland
|
Janssen Biologics (Ireland)
|
Ireland
|
Janssen Biologics B.V.
|
Netherlands
|
Janssen Cilag Farmaceutica S.A.
|
Argentina
|
Janssen de Mexico S. de R.L. de C.V.
|
Mexico
|
Janssen Inc.
|
Canada
|
Janssen Infectious Diseases-Diagnostics BVBA
|
Belgium
|
Janssen Korea Ltd.
|
Korea, Republic of
|
Janssen Pharmaceutica NV
|
Belgium
|
Janssen Pharmaceutical
|
Ireland
|
Janssen Pharmaceutical Holdings
|
Ireland
|
Janssen Pharmaceutical K.K.
|
Japan
|
Janssen R&D Ireland
|
Ireland
|
Janssen-Cilag
|
France
|
Janssen-Cilag AB
|
Sweden
|
Janssen-Cilag AG
|
Switzerland
|
Janssen-Cilag B.V.
|
Netherlands
|
Janssen-Cilag Farmaceutica Ltda.
|
Brazil
|
Janssen-Cilag Farmaceutica, Lda.
|
Portugal
|
Janssen-Cilag GmbH
|
Germany
|
Name of Subsidiary
|
Jurisdiction of Organization
|
Janssen Cilag Limited
|
Thailand
|
Janssen-Cilag Limited
|
United Kingdom
|
Janssen-Cilag NV
|
Belgium
|
Janssen-Cilag OY
|
Finland
|
Janssen-Cilag Pharma GmbH
|
Austria
|
Janssen-Cilag Pharmaceutical S.A.C.I.
|
Greece
|
Janssen-Cilag Pty Ltd
|
Australia
|
Janssen-Cilag S.p.A.
|
Italy
|
Janssen-Cilag, C.A.
|
Venezuela
|
Janssen-Cilag, S.A.
|
Spain
|
Janssen-Cilag, S.A. de C.V.
|
Mexico
|
J-C Health Care Ltd.
|
Israel
|
JJC Acquisition Company B.V.
|
Netherlands
|
Johnson & Johnson (China) Investment Ltd.
|
China
|
Johnson & Johnson (China) Ltd.
|
China
|
Johnson & Johnson (Hong Kong) Limited
|
Hong Kong
|
Johnson & Johnson (Ireland) Limited
|
Ireland
|
Johnson & Johnson (New Zealand) Limited
|
New Zealand
|
Johnson & Johnson (Philippines), Inc.
|
Philippines
|
Johnson & Johnson (Proprietary) Limited
|
South Africa
|
Johnson & Johnson (Thailand) Ltd.
|
Thailand
|
Johnson & Johnson AB
|
Sweden
|
Johnson & Johnson AG
|
Switzerland
|
Johnson & Johnson Consumer (Thailand) Limited
|
Thailand
|
Johnson & Johnson Consumer B.V.
|
Netherlands
|
Johnson & Johnson Consumer Holdings France
|
France
|
Johnson & Johnson Consumer Services EAME Ltd.
|
United Kingdom
|
Johnson & Johnson de Argentina S.A.C. e. I.
|
Argentina
|
Johnson & Johnson de Chile S.A.
|
Chile
|
Johnson & Johnson de Colombia S.A.
|
Colombia
|
Johnson & Johnson de Mexico, S.A. de C.V.
|
Mexico
|
Johnson & Johnson de Venezuela, S.A.
|
Venezuela
|
Johnson & Johnson del Ecuador S.A.
|
Ecuador
|
Johnson & Johnson del Peru S.A.
|
Peru
|
Johnson & Johnson do Brasil Industria E Comercio de Produtos Para Saude Ltda.
|
Brazil
|
Johnson & Johnson European Treasury Company
|
Ireland
|
Johnson & Johnson Finance Limited
|
United Kingdom
|
Johnson & Johnson Financial Services GmbH
|
Germany
|
Johnson & Johnson Gesellschaft m.b.H.
|
Austria
|
Johnson & Johnson GmbH
|
Germany
|
Johnson & Johnson Group Holdings GmbH
|
Germany
|
Johnson & Johnson Hellas Commercial and Industrial S.A.
|
Greece
|
Johnson & Johnson Holding GmbH
|
Germany
|
Johnson & Johnson Inc.
|
Canada
|
Johnson & Johnson Industrial Ltda.
|
Brazil
|
Johnson & Johnson International Financial Services Company
|
Ireland
|
Johnson & Johnson K.K.
|
Japan
|
Johnson & Johnson Kft.
|
Hungary
|
Name of Subsidiary
|
Jurisdiction of Organization
|
Johnson & Johnson Korea Selling & Distribution Limited Liability Company
|
Korea, Republic of
|
Johnson & Johnson Korea, Ltd.
|
Korea, Republic of
|
Johnson & Johnson Limitada
|
Portugal
|
Johnson & Johnson Limited
|
India
|
Johnson & Johnson Limited
|
United Kingdom
|
Johnson & Johnson LLC
|
Russian Federation
|
Johnson & Johnson Luxembourg Finance Company Sarl
|
Luxembourg
|
Johnson & Johnson Management Limited
|
United Kingdom
|
Johnson & Johnson Medical (China) Ltd.
|
China
|
Johnson & Johnson Medical (Pty) Limited
|
South Africa
|
Johnson & Johnson Medical (Shanghai) Ltd.
|
China
|
Johnson & Johnson Medical (Suzhou) Ltd.
|
China
|
Johnson & Johnson Medical B.V.
|
Netherlands
|
Johnson & Johnson Medical GmbH
|
Germany
|
Johnson & Johnson Medical Korea Limited
|
Korea, Republic of
|
Johnson & Johnson Medical Limited
|
United Kingdom
|
Johnson & Johnson Medical Mexico, S.A. de C.V.
|
Mexico
|
Johnson & Johnson Medical NV
|
Belgium
|
Johnson & Johnson Medical Products GmbH
|
Austria
|
Johnson & Johnson Medical Pty Ltd
|
Australia
|
Johnson & Johnson Medical S.A.
|
Argentina
|
Johnson & Johnson Medical S.p.A.
|
Italy
|
Johnson & Johnson Medical, S.C.S.
|
Venezuela
|
Johnson & Johnson Middle East FZ-LLC
|
United Arab Emirates
|
Johnson & Johnson Pacific Pty. Limited
|
Australia
|
Johnson & Johnson Poland Sp. z o.o.
|
Poland
|
Johnson & Johnson Pte. Ltd.
|
Singapore
|
Johnson & Johnson Pty. Limited
|
Australia
|
Johnson & Johnson S.p.A.
|
Italy
|
Johnson & Johnson SDN. BHD.
|
Malaysia
|
Johnson & Johnson Sihhi Malzeme Sanayi Ve Ticaret Limited Sirketi
|
Turkey
|
Johnson & Johnson Swiss Finance Company Limited
|
United Kingdom
|
Johnson & Johnson Taiwan Ltd.
|
Taiwan
|
Johnson & Johnson Vision Care (Ireland)
|
Ireland
|
Johnson & Johnson, prodaja medicinskih in farmacevtskih izdelkov, d.o.o.
|
Slovenia
|
Johnson & Johnson, S.A.
|
Spain
|
Johnson & Johnson, S.A. de C.V.
|
Mexico
|
Johnson & Johnson, s.r.o.
|
Czech Republic
|
Latam International Investment Company
|
Ireland
|
Latam Properties Holdings
|
Ireland
|
LifeScan Scotland Limited
|
United Kingdom
|
McNeil AB
|
Sweden
|
McNeil GmbH & Co. oHG
|
Germany
|
McNeil Healthcare (UK) Limited
|
United Kingdom
|
McNeil Manufacturing Pty Ltd
|
Australia
|
McNeil Products Limited
|
United Kingdom
|
McNeil Sweden AB
|
Sweden
|
Name of Subsidiary
|
Jurisdiction of Organization
|
Medos International Sarl
|
Switzerland
|
Medos Sarl
|
Switzerland
|
Mentor Medical Systems B.V.
|
Netherlands
|
Mentor Medical Systems C.V.
|
Netherlands
|
OBTECH Medical Sarl
|
Switzerland
|
OMJ Ireland
|
Ireland
|
OMJ PR Holdings
|
Ireland
|
Omrix Biopharmaceuticals Ltd.
|
Israel
|
Ortho-Clinical Diagnostics
|
France
|
Ortho-Clinical Diagnostics
|
United Kingdom
|
Ortho-Clinical Diagnostics GmbH
|
Germany
|
Ortho-Clinical Diagnostics K.K.
|
Japan
|
Ortho-Clinical Diagnostics NV
|
Belgium
|
P.T. Johnson & Johnson Indonesia
|
Indonesia
|
Shanghai Johnson & Johnson Pharmaceuticals, Ltd.
|
China
|
Synthes (Shanghai) Medical Trading Co., Ltd.
|
China
|
Synthes (Suzhou) Medical Co., Ltd.
|
China
|
Synthes Australia Pty Ltd
|
Australia
|
Synthes Canada, Ltd.
|
Canada
|
Synthes Colombia S.A.S.
|
Colombia
|
SYNTHES Deutschland Holding GmbH
|
Germany
|
Synthes Finanz AG
|
Switzerland
|
SYNTHES GmbH
|
Germany
|
Synthes GmbH
|
Switzerland
|
Synthes Holding AG
|
Switzerland
|
Synthes Industria e Comercio Ltda.
|
Brazil
|
Synthes K.K.
|
Japan
|
Synthes Limited
|
United Kingdom
|
Synthes Lux Finance S.àr.l.
|
Luxembourg
|
Synthes Lux Holding S.àr.l.
|
Luxembourg
|
Synthes Luxembourg, S.àr.l.
|
Luxembourg
|
Synthes Medical Private Limited
|
India
|
Synthes Produktions GmbH
|
Switzerland
|
Synthes S.r.l.
|
Italy
|
Synthes Tuttlingen GmbH
|
Germany
|
Synthes-Stratec S.A.
|
Spain
|
Tasmanian Alkaloids Pty. Ltd.
|
Australia
|
Tibotec-Virco Comm. VA
|
Belgium
|
Turnbuckle Investment Company
|
Ireland
|
Vania Expansion
|
France
|
Xian-Janssen Pharmaceutical Ltd.
|
China
|
|
|
|
|
|
|
|
Alex Gorsky
|
|
Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
Dominic J. Caruso
|
|
Chief Financial Officer
|
|
|
(1)
|
the Company's Annual Report on Form 10-K for the fiscal year ended December 30, 2012 (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and
|
(2)
|
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
|
|
|
|
|
|
Alex Gorsky
|
|
Chief Executive Officer
|
|
|
(1)
|
the Company's Annual Report on Form 10-K for the fiscal year ended December 30, 2012 (the “Report") fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and
|
(2)
|
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
|
|
|
|
Dominic J. Caruso
|
|
Chief Financial Officer
|
|
|